{
 "disease": "acute-lymphoblastic-leukemia",
 "label": "Acute lymphoblastic leukemia",
 "url": "https://usebiotransfer.org/disease/acute-lymphoblastic-leukemia/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "a19b406a66da",
  "targets": "3ef0cafe8d5e"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "CD19",
   "ensembl": "ENSG00000177455",
   "n_drug_entries": 14,
   "n_distinct_drugs": 14,
   "drugs": {
    "AXICABTAGENE CILOLEUCEL": "APPROVAL",
    "BLINATUMOMAB": "APPROVAL",
    "BREXUCABTAGENE AUTOLEUCEL": "APPROVAL",
    "COLTUXIMAB RAVTANSINE": "PHASE_2",
    "DENINTUZUMAB MAFODOTIN": "PHASE_2",
    "INEBILIZUMAB": "APPROVAL",
    "LISOCABTAGENE MARALEUCEL": "APPROVAL",
    "LONCASTUXIMAB TESIRINE": "APPROVAL",
    "MDX-1342": "PHASE_2",
    "OBECABTAGENE AUTOLEUCEL": "APPROVAL",
    "OBEXELIMAB": "PHASE_3",
    "ONCOLYSIN B": "PHASE_2",
    "TAFASITAMAB": "APPROVAL",
    "TISAGENLECLEUCEL": "APPROVAL"
   },
   "approved": [
    "AXICABTAGENE CILOLEUCEL",
    "BLINATUMOMAB",
    "BREXUCABTAGENE AUTOLEUCEL",
    "INEBILIZUMAB",
    "LISOCABTAGENE MARALEUCEL",
    "LONCASTUXIMAB TESIRINE",
    "OBECABTAGENE AUTOLEUCEL",
    "TAFASITAMAB",
    "TISAGENLECLEUCEL"
   ],
   "n_approved": 9,
   "approved_for": {
    "AXICABTAGENE CILOLEUCEL": [
     "diffuse large B-cell lymphoma",
     "follicular lymphoma"
    ],
    "BLINATUMOMAB": [
     "acute lymphoblastic leukemia",
     "B-cell acute lymphoblastic leukemia",
     "lymphoid leukemia"
    ],
    "BREXUCABTAGENE AUTOLEUCEL": [
     "mantle cell lymphoma"
    ],
    "INEBILIZUMAB": [
     "neuromyelitis optica"
    ],
    "LISOCABTAGENE MARALEUCEL": [
     "diffuse large B-cell lymphoma",
     "follicular lymphoma",
     "neoplasm of mediastinum"
    ],
    "LONCASTUXIMAB TESIRINE": [
     "diffuse large B-cell lymphoma",
     "B-cell neoplasm",
     "B-cell non-Hodgkin lymphoma"
    ],
    "OBECABTAGENE AUTOLEUCEL": [
     "B-cell acute lymphoblastic leukemia"
    ],
    "TAFASITAMAB": [
     "diffuse large B-cell lymphoma",
     "lymphoma"
    ],
    "TISAGENLECLEUCEL": [
     "diffuse large B-cell lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "CD22",
   "ensembl": "ENSG00000012124",
   "n_drug_entries": 11,
   "n_distinct_drugs": 11,
   "drugs": {
    "BECTUMOMAB": "PHASE_3",
    "BL22": "PHASE_2",
    "EPRATUZUMAB": "PHASE_3",
    "EPRATUZUMAB-CYS-TESIRINE": "PHASE_1_2",
    "INOTUZUMAB": "PHASE_3",
    "INOTUZUMAB OZOGAMICIN": "APPROVAL",
    "MONO-DGA-RFB4": "PHASE_1",
    "MOXETUMOMAB PASUDOTOX": "APPROVAL",
    "PINATUZUMAB VEDOTIN": "PHASE_2",
    "YTTRIUM Y 90 EPRATUZUMAB": "PHASE_1_2",
    "YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN": "PHASE_2"
   },
   "approved": [
    "INOTUZUMAB OZOGAMICIN",
    "MOXETUMOMAB PASUDOTOX"
   ],
   "n_approved": 2,
   "approved_for": {
    "INOTUZUMAB OZOGAMICIN": [
     "acute lymphoblastic leukemia",
     "B-cell acute lymphoblastic leukemia"
    ],
    "MOXETUMOMAB PASUDOTOX": [
     "hairy cell leukemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "ABL1",
   "ensembl": "ENSG00000097007",
   "n_drug_entries": 27,
   "n_distinct_drugs": 21,
   "drugs": {
    "ASCIMINIB": "APPROVAL",
    "AT-9283": "PHASE_3",
    "AZD-0424": "PHASE_1",
    "BAFETINIB": "PHASE_2",
    "BOSUTINIB": "APPROVAL",
    "DASATINIB": "APPROVAL",
    "FLUMATINIB": "PHASE_3",
    "IMATINIB": "APPROVAL",
    "KW-2449": "PHASE_1",
    "NILOTINIB": "APPROVAL",
    "NILOTINIB HYDROCHLORIDE": "APPROVAL",
    "OLVEREMBATINIB": "PHASE_3",
    "PONATINIB": "APPROVAL",
    "RADOTINIB": "PHASE_3",
    "REBASTINIB": "PHASE_1_2",
    "REGORAFENIB": "APPROVAL",
    "RUSERONTINIB": "PHASE_3",
    "SARACATINIB": "PHASE_2_3",
    "UMBRALISIB": "APPROVAL",
    "VODOBATINIB": "PHASE_2",
    "XL-228": "PHASE_1"
   },
   "approved": [
    "ASCIMINIB",
    "BOSUTINIB",
    "DASATINIB",
    "IMATINIB",
    "NILOTINIB",
    "NILOTINIB HYDROCHLORIDE",
    "PONATINIB",
    "REGORAFENIB",
    "UMBRALISIB"
   ],
   "n_approved": 9,
   "approved_for": {
    "ASCIMINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "BOSUTINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "myeloid leukemia",
     "breast cancer"
    ],
    "DASATINIB": [
     "acute lymphoblastic leukemia",
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "lymphoid leukemia"
    ],
    "IMATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "hypereosinophilic syndrome",
     "myelodysplastic/myeloproliferative disease",
     "dermatofibrosarcoma protuberans",
     "gastrointestinal stromal tumor",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "B-cell acute lymphoblastic leukemia"
    ],
    "NILOTINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "NILOTINIB HYDROCHLORIDE": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "PONATINIB": [
     "lymphoid leukemia",
     "myeloid leukemia",
     "acute lymphoblastic leukemia",
     "chronic myelogenous leukemia, BCR-ABL1 positive"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "UMBRALISIB": [
     "follicular lymphoma",
     "marginal zone lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "IKZF1",
   "ensembl": "ENSG00000185811",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "NOTCH1",
   "ensembl": "ENSG00000148400",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "BRONTICTUZUMAB": "PHASE_1"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "KMT2A",
   "ensembl": "ENSG00000118058",
   "n_drug_entries": 2,
   "n_distinct_drugs": 2,
   "drugs": {
    "REVUMENIB": "PHASE_3",
    "REVUMENIB SESQUIFUMARATE": "PHASE_1_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "ETV6",
   "ensembl": "ENSG00000139083",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "PAX5",
   "ensembl": "ENSG00000196092",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "CRLF2",
   "ensembl": "ENSG00000292363",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "JAK2",
   "ensembl": "ENSG00000096968",
   "n_drug_entries": 31,
   "n_distinct_drugs": 26,
   "drugs": {
    "AC-430": "PHASE_1",
    "AT-9283": "PHASE_3",
    "AZD-1480": "PHASE_2",
    "BARICITINIB": "APPROVAL",
    "BMS-911543": "PHASE_2",
    "CT-1578": "PHASE_1",
    "DELGOCITINIB": "APPROVAL",
    "DEURUXOLITINIB": "APPROVAL",
    "FEDRATINIB": "APPROVAL",
    "FILGOTINIB": "APPROVAL",
    "GANDOTINIB": "PHASE_2",
    "GUSACITINIB": "PHASE_2",
    "IZENCITINIB": "PHASE_2_3",
    "LESTAURTINIB": "APPROVAL",
    "MOMELOTINIB": "APPROVAL",
    "MOMELOTINIB DIHYDROCHLORIDE": "APPROVAL",
    "NEZULCITINIB": "PHASE_2",
    "NS-018": "PHASE_2",
    "PACRITINIB": "APPROVAL",
    "PEFICITINIB": "PHASE_3",
    "RUXOLITINIB": "APPROVAL",
    "TOFACITINIB": "APPROVAL",
    "UPADACITINIB": "APPROVAL",
    "UPADACITINIB HEMIHYDRATE": "APPROVAL",
    "XL-019": "PHASE_3",
    "ZOTIRACICLIB": "PHASE_1_2"
   },
   "approved": [
    "BARICITINIB",
    "DELGOCITINIB",
    "DEURUXOLITINIB",
    "FEDRATINIB",
    "FILGOTINIB",
    "LESTAURTINIB",
    "MOMELOTINIB",
    "MOMELOTINIB DIHYDROCHLORIDE",
    "PACRITINIB",
    "RUXOLITINIB",
    "TOFACITINIB",
    "UPADACITINIB",
    "UPADACITINIB HEMIHYDRATE"
   ],
   "n_approved": 13,
   "approved_for": {
    "BARICITINIB": [
     "juvenile idiopathic arthritis",
     "atopic eczema",
     "rheumatoid arthritis",
     "juvenile dermatomyositis"
    ],
    "DELGOCITINIB": [
     "atopic eczema",
     "Eczematoid dermatitis",
     "dermatitis"
    ],
    "DEURUXOLITINIB": [
     "alopecia areata"
    ],
    "FEDRATINIB": [
     "myeloproliferative disorder",
     "primary myelofibrosis",
     "myelofibrosis",
     "acquired polycythemia vera"
    ],
    "FILGOTINIB": [
     "rheumatoid arthritis"
    ],
    "LESTAURTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "MOMELOTINIB": [
     "myelofibrosis"
    ],
    "MOMELOTINIB DIHYDROCHLORIDE": [
     "myelofibrosis",
     "Splenomegaly",
     "myeloproliferative disorder"
    ],
    "PACRITINIB": [
     "myelofibrosis",
     "primary myelofibrosis",
     "acquired polycythemia vera"
    ],
    "RUXOLITINIB": [
     "essential thrombocythemia",
     "myelofibrosis",
     "Eczematoid dermatitis",
     "myeloproliferative disorder",
     "graft versus host disease",
     "acquired polycythemia vera",
     "chronic graft versus host disease",
     "vitiligo",
     "primary myelofibrosis"
    ],
    "TOFACITINIB": [
     "psoriatic arthritis",
     "rheumatoid arthritis"
    ],
    "UPADACITINIB": [
     "rheumatoid arthritis",
     "atopic eczema",
     "ulcerative colitis",
     "Crohn disease",
     "psoriatic arthritis",
     "temporal arteritis",
     "ankylosing spondylitis"
    ],
    "UPADACITINIB HEMIHYDRATE": [
     "rheumatoid arthritis",
     "ulcerative colitis"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "CD19": {
    "n": 327,
    "n_observational": 15,
    "n_active": 186,
    "n_withdrawn": 15,
    "trials": [
     {
      "nct": "NCT01371630",
      "title": "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02508038",
      "title": "Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02877303",
      "title": "Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03150693",
      "title": "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03263572",
      "title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03595917",
      "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",
      "status": "RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03643276",
      "title": "Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017",
      "status": "RECRUITING",
      "last_update": "2025-04-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03666000",
      "title": "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03739814",
      "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03810196",
      "title": "CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCR\u03b1\u03b2/CD19 Depleted HSCT",
      "status": "RECRUITING",
      "last_update": "2026-07-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03959085",
      "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04094311",
      "title": "Study of Out of Specification for Tisagenlecleucel",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04260022",
      "title": "Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04276870",
      "title": "Orphan Indications for CD19 Redirected Autologous T Cells",
      "status": "RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04307576",
      "title": "A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04512716",
      "title": "Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04532281",
      "title": "A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2020-10-26",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04544592",
      "title": "UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546399",
      "title": "A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603872",
      "title": "CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2020-10-28",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04684147",
      "title": "Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04746209",
      "title": "Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT",
      "status": "RECRUITING",
      "last_update": "2021-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04836507",
      "title": "Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05029531",
      "title": "Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)",
      "status": "RECRUITING",
      "last_update": "2024-06-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05054257",
      "title": "CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05310591",
      "title": "Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence",
      "status": "RECRUITING",
      "last_update": "2024-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327894",
      "title": "Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05418088",
      "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05442515",
      "title": "CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05519579",
      "title": "Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05645718",
      "title": "Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05667506",
      "title": "A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)",
      "status": "RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05794880",
      "title": "MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800210",
      "title": "Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05827549",
      "title": "Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05848687",
      "title": "TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",
      "status": "RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06061094",
      "title": "Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT",
      "status": "RECRUITING",
      "last_update": "2025-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06080191",
      "title": "Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06081478",
      "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2023-10-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06101381",
      "title": "CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-12-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06124157",
      "title": "A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06144606",
      "title": "Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06173518",
      "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",
      "status": "RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06220487",
      "title": "A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL",
      "status": "RECRUITING",
      "last_update": "2024-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06227026",
      "title": "Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06237192",
      "title": "MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients",
      "status": "RECRUITING",
      "last_update": "2024-02-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06250959",
      "title": "RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.",
      "status": "RECRUITING",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06257394",
      "title": "Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06287229",
      "title": "Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06308588",
      "title": "Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06317662",
      "title": "Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06339775",
      "title": "Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation",
      "status": "RECRUITING",
      "last_update": "2024-04-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06355739",
      "title": "CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+",
      "status": "RECRUITING",
      "last_update": "2024-04-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06387121",
      "title": "Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06393985",
      "title": "Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06408194",
      "title": "Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06507514",
      "title": "Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06508775",
      "title": "Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies",
      "status": "RECRUITING",
      "last_update": "2025-11-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533748",
      "title": "Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06554626",
      "title": "Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06607419",
      "title": "Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2024-09-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06659653",
      "title": "Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.",
      "status": "RECRUITING",
      "last_update": "2024-10-26",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06709469",
      "title": "Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults",
      "status": "RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06718244",
      "title": "Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1",
      "status": "RECRUITING",
      "last_update": "2025-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06735495",
      "title": "CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors",
      "status": "RECRUITING",
      "last_update": "2024-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06742515",
      "title": "Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06752785",
      "title": "CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.",
      "status": "RECRUITING",
      "last_update": "2024-12-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764238",
      "title": "Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06847269",
      "title": "CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06860269",
      "title": "A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06866873",
      "title": "CD-19 CAR-T Cell for Pediatric ALL or Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-03-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06879340",
      "title": "Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880913",
      "title": "Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06882057",
      "title": "Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2025-08-26",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06886074",
      "title": "Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06890494",
      "title": "Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985485",
      "title": "Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07003737",
      "title": "Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07008885",
      "title": "BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07053059",
      "title": "Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07059156",
      "title": "Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL",
      "status": "RECRUITING",
      "last_update": "2025-07-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07066397",
      "title": "A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-07-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07072494",
      "title": "CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study",
      "status": "RECRUITING",
      "last_update": "2025-07-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07074496",
      "title": "Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07105579",
      "title": "Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07133997",
      "title": "Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07152041",
      "title": "Newly-diagnosed Pediatric Ph-positive B-ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07205315",
      "title": "A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia",
      "status": "RECRUITING",
      "last_update": "2026-07-20",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227584",
      "title": "ALL Backbone in AYAs",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07244406",
      "title": "Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07284927",
      "title": "Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07312630",
      "title": "Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07371403",
      "title": "MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387926",
      "title": "Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07400029",
      "title": "A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07429461",
      "title": "Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-02-24",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07454226",
      "title": "ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493161",
      "title": "Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07495631",
      "title": "Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07502118",
      "title": "NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07564453",
      "title": "Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07570173",
      "title": "A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07573111",
      "title": "Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07575971",
      "title": "Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07677878",
      "title": "Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07695012",
      "title": "CAR-T Cell Therapy for ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00560794",
      "title": "Phase II Study of the BiTE\u00ae Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2015-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00643240",
      "title": "Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-11-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00816413",
      "title": "Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00840853",
      "title": "Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00961142",
      "title": "Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01195480",
      "title": "CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2018-05-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207388",
      "title": "Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01209286",
      "title": "Study of the BiTE\u00ae Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2017-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01362452",
      "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells",
      "status": "COMPLETED",
      "last_update": "2017-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01408160",
      "title": "Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2019-09-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01466179",
      "title": "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01471782",
      "title": "Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-02-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01475058",
      "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant",
      "status": "COMPLETED",
      "last_update": "2017-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01497184",
      "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood",
      "status": "COMPLETED",
      "last_update": "2025-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01517035",
      "title": "Improving Blood Stem Cell Collection and Transplant Procedures",
      "status": "COMPLETED",
      "last_update": "2018-07-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01683279",
      "title": "A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01786135",
      "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01864889",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19",
      "status": "UNKNOWN",
      "last_update": "2016-01-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01865617",
      "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01974479",
      "title": "Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia",
      "status": "SUSPENDED",
      "last_update": "2019-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02000427",
      "title": "Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2024-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02003222",
      "title": "Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02013167",
      "title": "Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2024-03-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02101853",
      "title": "Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02143414",
      "title": "Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02146924",
      "title": "Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02167360",
      "title": "Study of Efficacy and Safety of CTL019 in Adult ALL Patients",
      "status": "WITHDRAWN",
      "last_update": "2017-02-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02186860",
      "title": "Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-02-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02228096",
      "title": "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients",
      "status": "COMPLETED",
      "last_update": "2020-11-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02274506",
      "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells",
      "status": "WITHDRAWN",
      "last_update": "2020-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02374333",
      "title": "Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy",
      "status": "COMPLETED",
      "last_update": "2021-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02393859",
      "title": "Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2026-06-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02412306",
      "title": "Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-12-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02435849",
      "title": "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients",
      "status": "COMPLETED",
      "last_update": "2024-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02458014",
      "title": "Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease",
      "status": "COMPLETED",
      "last_update": "2025-09-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02529813",
      "title": "CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535364",
      "title": "Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "TERMINATED",
      "last_update": "2020-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02614066",
      "title": "A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)",
      "status": "COMPLETED",
      "last_update": "2024-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02625480",
      "title": "Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-04-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02744768",
      "title": "D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2018-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02790515",
      "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02799550",
      "title": "Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL",
      "status": "UNKNOWN",
      "last_update": "2019-02-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02807883",
      "title": "Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02819583",
      "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-10-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02848911",
      "title": "Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL",
      "status": "TERMINATED",
      "last_update": "2019-06-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02851589",
      "title": "Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02879695",
      "title": "Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02892695",
      "title": "PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02935543",
      "title": "CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL",
      "status": "TERMINATED",
      "last_update": "2023-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02968472",
      "title": "A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia",
      "status": "UNKNOWN",
      "last_update": "2016-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02975687",
      "title": "CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02997761",
      "title": "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03076437",
      "title": "Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03103971",
      "title": "huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2024-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03109093",
      "title": "Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03110640",
      "title": "Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2019-11-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03114865",
      "title": "A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03117751",
      "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03123939",
      "title": "Phase III B in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-07-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03147612",
      "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03160079",
      "title": "Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts",
      "status": "COMPLETED",
      "last_update": "2025-11-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03185494",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
      "status": "UNKNOWN",
      "last_update": "2019-04-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03186118",
      "title": "Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03191773",
      "title": "A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2017-06-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03229876",
      "title": "Safety and Efficacy Evaluation of CD19-UCART",
      "status": "SUSPENDED",
      "last_update": "2023-07-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03233854",
      "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241940",
      "title": "Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03265106",
      "title": "A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects",
      "status": "UNKNOWN",
      "last_update": "2021-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03289455",
      "title": "CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03298828",
      "title": "CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2017-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03321123",
      "title": "MB-CART19.1 in Patients With R/R ALL",
      "status": "UNKNOWN",
      "last_update": "2017-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03327285",
      "title": "C-CAR011 Treatment in Subjects With ALL After HSCT",
      "status": "UNKNOWN",
      "last_update": "2020-10-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03366350",
      "title": "Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2019-05-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03367299",
      "title": "Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03389035",
      "title": "Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT",
      "status": "COMPLETED",
      "last_update": "2023-05-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03423706",
      "title": "Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation",
      "status": "UNKNOWN",
      "last_update": "2019-12-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03476239",
      "title": "Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2023-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03480438",
      "title": "Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab",
      "status": "COMPLETED",
      "last_update": "2025-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03512405",
      "title": "Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03518112",
      "title": "Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03523429",
      "title": "PETHEMA-BLIN-01/PET069014 (BLIN-01)",
      "status": "TERMINATED",
      "last_update": "2022-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03541083",
      "title": "Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03559439",
      "title": "CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2020-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03573700",
      "title": "Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03599375",
      "title": "Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2019-02-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03620058",
      "title": "CART22 Alone or in Combination With huCART19 for ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03628053",
      "title": "Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2020-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03642626",
      "title": "MT2017-45: CAR-T Cell Therapy for Heme Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03671460",
      "title": "CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.",
      "status": "UNKNOWN",
      "last_update": "2018-09-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03709719",
      "title": "Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2021-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03743246",
      "title": "A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)",
      "status": "TERMINATED",
      "last_update": "2024-08-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03751709",
      "title": "Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL",
      "status": "COMPLETED",
      "last_update": "2025-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03754764",
      "title": "A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy",
      "status": "UNKNOWN",
      "last_update": "2018-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03792633",
      "title": "Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL",
      "status": "COMPLETED",
      "last_update": "2025-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03798509",
      "title": "Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849651",
      "title": "TCR\u03b1\u03b2-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03853616",
      "title": "MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03876769",
      "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03902197",
      "title": "CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients",
      "status": "UNKNOWN",
      "last_update": "2019-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03914625",
      "title": "A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919526",
      "title": "Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor\uff08CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL",
      "status": "COMPLETED",
      "last_update": "2023-12-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03982992",
      "title": "Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab",
      "status": "WITHDRAWN",
      "last_update": "2024-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03984968",
      "title": "CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04000698",
      "title": "Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias",
      "status": "UNKNOWN",
      "last_update": "2020-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04034446",
      "title": "CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044560",
      "title": "Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2022-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04049383",
      "title": "CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL",
      "status": "TERMINATED",
      "last_update": "2026-01-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04094766",
      "title": "Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2020-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04129099",
      "title": "A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL",
      "status": "UNKNOWN",
      "last_update": "2020-05-28",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04154709",
      "title": "CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2020-01-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04156659",
      "title": "Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL",
      "status": "WITHDRAWN",
      "last_update": "2023-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04166838",
      "title": "The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "UNKNOWN",
      "last_update": "2019-11-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04191941",
      "title": "Treatment of Hematological Malignancy With Novel CAR-T Cells.",
      "status": "UNKNOWN",
      "last_update": "2019-12-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04206943",
      "title": "Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL",
      "status": "UNKNOWN",
      "last_update": "2020-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04214886",
      "title": "CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2022-08-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04225676",
      "title": "Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2023-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04230473",
      "title": "A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04264039",
      "title": "Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies",
      "status": "UNKNOWN",
      "last_update": "2020-02-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04289220",
      "title": "Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04303520",
      "title": "Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL",
      "status": "UNKNOWN",
      "last_update": "2020-03-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04325841",
      "title": "Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children",
      "status": "COMPLETED",
      "last_update": "2025-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04329325",
      "title": "Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04334993",
      "title": "Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study",
      "status": "UNKNOWN",
      "last_update": "2021-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04340154",
      "title": "Study of Sequential CAR-T Cell Treating Leukemia Children",
      "status": "TERMINATED",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04404660",
      "title": "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04448834",
      "title": "Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL",
      "status": "WITHDRAWN",
      "last_update": "2022-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04499573",
      "title": "Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-02-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04506086",
      "title": "Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2025-05-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04516551",
      "title": "Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT",
      "status": "UNKNOWN",
      "last_update": "2020-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04521231",
      "title": "A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04524455",
      "title": "Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL",
      "status": "COMPLETED",
      "last_update": "2024-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04530565",
      "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04554485",
      "title": "Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04556084",
      "title": "Blinatumomab Bridging Therapy for BALL",
      "status": "TERMINATED",
      "last_update": "2025-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04604691",
      "title": "Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)",
      "status": "UNKNOWN",
      "last_update": "2022-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626726",
      "title": "Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation",
      "status": "UNKNOWN",
      "last_update": "2020-11-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626765",
      "title": "CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2020-11-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04688983",
      "title": "Study in Adult Ph-positive ALL",
      "status": "UNKNOWN",
      "last_update": "2020-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04689204",
      "title": "A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-01-24",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04722848",
      "title": "Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04723342",
      "title": "Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot",
      "status": "UNKNOWN",
      "last_update": "2021-01-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04723901",
      "title": "Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-01-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04785547",
      "title": "ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT",
      "status": "TERMINATED",
      "last_update": "2024-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844086",
      "title": "RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies",
      "status": "TERMINATED",
      "last_update": "2022-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04872790",
      "title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04888468",
      "title": "Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents",
      "status": "COMPLETED",
      "last_update": "2022-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04994717",
      "title": "Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05037669",
      "title": "Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05164042",
      "title": "Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-12-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05168748",
      "title": "CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2022-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05182385",
      "title": "Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05192889",
      "title": "Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05225831",
      "title": "Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-02-07",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05236764",
      "title": "Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303792",
      "title": "Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05381181",
      "title": "Safety and Efficacy Evaluation of Next-generation CD19-UCART",
      "status": "UNKNOWN",
      "last_update": "2023-01-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05410041",
      "title": "Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2022-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429905",
      "title": "Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia",
      "status": "UNKNOWN",
      "last_update": "2023-03-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05453500",
      "title": "Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05460533",
      "title": "A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05487651",
      "title": "Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2023-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05513612",
      "title": "Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2023-03-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05557110",
      "title": "Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05559450",
      "title": "Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL",
      "status": "UNKNOWN",
      "last_update": "2022-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05571540",
      "title": "Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL",
      "status": "WITHDRAWN",
      "last_update": "2022-11-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05613348",
      "title": "CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2024-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05651191",
      "title": "To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL",
      "status": "UNKNOWN",
      "last_update": "2022-12-14",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05654038",
      "title": "A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies",
      "status": "UNKNOWN",
      "last_update": "2022-12-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05707273",
      "title": "CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05727683",
      "title": "CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2023-02-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05747157",
      "title": "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research",
      "status": "UNKNOWN",
      "last_update": "2023-11-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05779930",
      "title": "Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05931757",
      "title": "A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05936229",
      "title": "Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy",
      "status": "WITHDRAWN",
      "last_update": "2024-07-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05968170",
      "title": "TCR\u03b1\u03b2/CD19 Depletion of Stem Cell Grafts for Transplant",
      "status": "WITHDRAWN",
      "last_update": "2025-07-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05993949",
      "title": "Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054113",
      "title": "Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06056752",
      "title": "QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2023-10-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06075238",
      "title": "Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06111625",
      "title": "Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL",
      "status": "UNKNOWN",
      "last_update": "2023-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06125106",
      "title": "Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab",
      "status": "UNKNOWN",
      "last_update": "2023-11-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253663",
      "title": "Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06367114",
      "title": "Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)",
      "status": "UNKNOWN",
      "last_update": "2024-04-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06393335",
      "title": "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research",
      "status": "UNKNOWN",
      "last_update": "2024-05-01",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06438796",
      "title": "Blinatumomab Maintenance After Allo-HSCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06447987",
      "title": "Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia",
      "status": "SUSPENDED",
      "last_update": "2026-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06631040",
      "title": "Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-10-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06641024",
      "title": "Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06649006",
      "title": "Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06658938",
      "title": "Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-10-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06763302",
      "title": "NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-01-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06773936",
      "title": "Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06894693",
      "title": "A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06930105",
      "title": "Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985498",
      "title": "Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL",
      "status": "SUSPENDED",
      "last_update": "2026-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06991920",
      "title": "Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07043218",
      "title": "A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07134088",
      "title": "A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07153796",
      "title": "A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07162571",
      "title": "This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07166419",
      "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07166549",
      "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07178912",
      "title": "Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07192237",
      "title": "Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07199855",
      "title": "Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223190",
      "title": "A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07283640",
      "title": "A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07297914",
      "title": "Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07301424",
      "title": "Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07313852",
      "title": "A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07335094",
      "title": "A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07443592",
      "title": "Treatment for Ph-negative ALL for Adults up to 65 Years",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476729",
      "title": "International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07491263",
      "title": "Clinical Study of Universal CD19 CAR-\u03b3\u03b4 T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07539610",
      "title": "Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07556757",
      "title": "A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07614022",
      "title": "A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07636564",
      "title": "Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07643103",
      "title": "Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07723911",
      "title": "A Study of Injectable BLB101 and Blincyto\u00ae in Adult Participants With R/R CD19+ B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07754682",
      "title": "Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 131,
     "n_observational": 4,
     "n_active": 59,
     "n_withdrawn": 10,
     "trials": [
      {
       "nct": "NCT03810196",
       "title": "CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCR\u03b1\u03b2/CD19 Depleted HSCT",
       "status": "RECRUITING",
       "last_update": "2026-07-08",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04276870",
       "title": "Orphan Indications for CD19 Redirected Autologous T Cells",
       "status": "RECRUITING",
       "last_update": "2026-03-06",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04512716",
       "title": "Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-02-17",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04532281",
       "title": "A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies",
       "status": "RECRUITING",
       "last_update": "2020-10-26",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04544592",
       "title": "UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",
       "status": "RECRUITING",
       "last_update": "2026-04-20",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04603872",
       "title": "CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies",
       "status": "RECRUITING",
       "last_update": "2020-10-28",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04746209",
       "title": "Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT",
       "status": "RECRUITING",
       "last_update": "2021-09-17",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05054257",
       "title": "CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma",
       "status": "RECRUITING",
       "last_update": "2025-01-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05418088",
       "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-05-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05442515",
       "title": "CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-07-30",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06080191",
       "title": "Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL",
       "status": "RECRUITING",
       "last_update": "2025-12-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06081478",
       "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2023-10-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06101381",
       "title": "CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma",
       "status": "RECRUITING",
       "last_update": "2024-12-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06173518",
       "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",
       "status": "RECRUITING",
       "last_update": "2026-03-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06227026",
       "title": "Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06355739",
       "title": "CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+",
       "status": "RECRUITING",
       "last_update": "2024-04-09",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06408194",
       "title": "Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-09-01",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06709469",
       "title": "Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults",
       "status": "RECRUITING",
       "last_update": "2025-09-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06735495",
       "title": "CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors",
       "status": "RECRUITING",
       "last_update": "2024-12-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06752785",
       "title": "CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.",
       "status": "RECRUITING",
       "last_update": "2024-12-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06847269",
       "title": "CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia",
       "status": "RECRUITING",
       "last_update": "2026-03-25",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06866873",
       "title": "CD-19 CAR-T Cell for Pediatric ALL or Lymphoma",
       "status": "RECRUITING",
       "last_update": "2025-03-10",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06880913",
       "title": "Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL",
       "status": "RECRUITING",
       "last_update": "2026-03-30",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07008885",
       "title": "BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL",
       "status": "RECRUITING",
       "last_update": "2025-06-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07066397",
       "title": "A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL",
       "status": "RECRUITING",
       "last_update": "2025-07-23",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07072494",
       "title": "CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study",
       "status": "RECRUITING",
       "last_update": "2025-07-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07074496",
       "title": "Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.",
       "status": "RECRUITING",
       "last_update": "2026-06-17",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07105579",
       "title": "Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2025-08-06",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07244406",
       "title": "Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL",
       "status": "RECRUITING",
       "last_update": "2025-11-24",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07371403",
       "title": "MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2026-08-05",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07575971",
       "title": "Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2026-06-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07695012",
       "title": "CAR-T Cell Therapy for ALL",
       "status": "RECRUITING",
       "last_update": "2026-07-10",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01362452",
       "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells",
       "status": "COMPLETED",
       "last_update": "2017-08-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01475058",
       "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant",
       "status": "COMPLETED",
       "last_update": "2017-02-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01497184",
       "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood",
       "status": "COMPLETED",
       "last_update": "2025-03-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01683279",
       "title": "A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01864889",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19",
       "status": "UNKNOWN",
       "last_update": "2016-01-28",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01865617",
       "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
       "status": "COMPLETED",
       "last_update": "2022-05-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02146924",
       "title": "Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02186860",
       "title": "Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-02-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02274506",
       "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells",
       "status": "WITHDRAWN",
       "last_update": "2020-01-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02374333",
       "title": "Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy",
       "status": "COMPLETED",
       "last_update": "2021-09-23",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02529813",
       "title": "CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies",
       "status": "COMPLETED",
       "last_update": "2022-06-30",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02790515",
       "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-08-12",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02799550",
       "title": "Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL",
       "status": "UNKNOWN",
       "last_update": "2019-02-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02819583",
       "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2016-10-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02935543",
       "title": "CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL",
       "status": "TERMINATED",
       "last_update": "2023-06-22",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02975687",
       "title": "CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia",
       "status": "COMPLETED",
       "last_update": "2025-06-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03076437",
       "title": "Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies",
       "status": "COMPLETED",
       "last_update": "2021-03-19",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03103971",
       "title": "huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
       "status": "TERMINATED",
       "last_update": "2024-04-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03110640",
       "title": "Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2019-11-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03185494",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
       "status": "UNKNOWN",
       "last_update": "2019-04-17",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03186118",
       "title": "Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03191773",
       "title": "A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2017-06-20",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03229876",
       "title": "Safety and Efficacy Evaluation of CD19-UCART",
       "status": "SUSPENDED",
       "last_update": "2023-07-24",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03233854",
       "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-11-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03241940",
       "title": "Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-30",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03289455",
       "title": "CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)",
       "status": "COMPLETED",
       "last_update": "2021-02-01",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03298828",
       "title": "CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2017-10-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03321123",
       "title": "MB-CART19.1 in Patients With R/R ALL",
       "status": "UNKNOWN",
       "last_update": "2017-10-25",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03366350",
       "title": "Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2019-05-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03559439",
       "title": "CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2020-11-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03573700",
       "title": "Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-11",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03599375",
       "title": "Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2019-02-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03620058",
       "title": "CART22 Alone or in Combination With huCART19 for ALL",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-10-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03642626",
       "title": "MT2017-45: CAR-T Cell Therapy for Heme Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-01-23",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03671460",
       "title": "CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.",
       "status": "UNKNOWN",
       "last_update": "2018-09-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03751709",
       "title": "Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL",
       "status": "COMPLETED",
       "last_update": "2025-02-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03754764",
       "title": "A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy",
       "status": "UNKNOWN",
       "last_update": "2018-12-07",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03792633",
       "title": "Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL",
       "status": "COMPLETED",
       "last_update": "2025-06-05",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03798509",
       "title": "Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-08-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03849651",
       "title": "TCR\u03b1\u03b2-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-22",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03853616",
       "title": "MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03902197",
       "title": "CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients",
       "status": "UNKNOWN",
       "last_update": "2019-04-08",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03919526",
       "title": "Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor\uff08CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL",
       "status": "COMPLETED",
       "last_update": "2023-12-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03982992",
       "title": "Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab",
       "status": "WITHDRAWN",
       "last_update": "2024-03-12",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03984968",
       "title": "CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-05-07",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04034446",
       "title": "CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)",
       "status": "TERMINATED",
       "last_update": "2025-06-03",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04049383",
       "title": "CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL",
       "status": "TERMINATED",
       "last_update": "2026-01-12",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04094766",
       "title": "Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia",
       "status": "WITHDRAWN",
       "last_update": "2020-11-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04129099",
       "title": "A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL",
       "status": "UNKNOWN",
       "last_update": "2020-05-28",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04154709",
       "title": "CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2020-01-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04166838",
       "title": "The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)",
       "status": "UNKNOWN",
       "last_update": "2019-11-18",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04191941",
       "title": "Treatment of Hematological Malignancy With Novel CAR-T Cells.",
       "status": "UNKNOWN",
       "last_update": "2019-12-10",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04206943",
       "title": "Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL",
       "status": "UNKNOWN",
       "last_update": "2020-01-27",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04214886",
       "title": "CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2022-08-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04264039",
       "title": "Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies",
       "status": "UNKNOWN",
       "last_update": "2020-02-11",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04289220",
       "title": "Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-05-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04303520",
       "title": "Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL",
       "status": "UNKNOWN",
       "last_update": "2020-03-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04325841",
       "title": "Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children",
       "status": "COMPLETED",
       "last_update": "2025-05-18",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04340154",
       "title": "Study of Sequential CAR-T Cell Treating Leukemia Children",
       "status": "TERMINATED",
       "last_update": "2024-12-05",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04404660",
       "title": "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-04-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04499573",
       "title": "Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2023-02-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04516551",
       "title": "Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT",
       "status": "UNKNOWN",
       "last_update": "2020-11-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04626726",
       "title": "Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation",
       "status": "UNKNOWN",
       "last_update": "2020-11-13",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04626765",
       "title": "CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2020-11-13",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04723901",
       "title": "Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-01-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04844086",
       "title": "RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies",
       "status": "TERMINATED",
       "last_update": "2022-05-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05037669",
       "title": "Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2023-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05164042",
       "title": "Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-12-20",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05168748",
       "title": "CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia",
       "status": "WITHDRAWN",
       "last_update": "2022-12-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05225831",
       "title": "Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2022-02-07",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05236764",
       "title": "Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-10-30",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05381181",
       "title": "Safety and Efficacy Evaluation of Next-generation CD19-UCART",
       "status": "UNKNOWN",
       "last_update": "2023-01-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05410041",
       "title": "Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2022-06-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05429905",
       "title": "Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia",
       "status": "UNKNOWN",
       "last_update": "2023-03-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05487651",
       "title": "Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2023-05-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05513612",
       "title": "Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies",
       "status": "WITHDRAWN",
       "last_update": "2023-03-01",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05571540",
       "title": "Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL",
       "status": "WITHDRAWN",
       "last_update": "2022-11-30",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05613348",
       "title": "CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2024-03-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05651191",
       "title": "To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL",
       "status": "UNKNOWN",
       "last_update": "2022-12-14",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05654038",
       "title": "A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies",
       "status": "UNKNOWN",
       "last_update": "2022-12-21",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05707273",
       "title": "CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-09-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05727683",
       "title": "CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2023-02-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05747157",
       "title": "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research",
       "status": "UNKNOWN",
       "last_update": "2023-11-21",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05779930",
       "title": "Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-08-15",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05936229",
       "title": "Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy",
       "status": "WITHDRAWN",
       "last_update": "2024-07-12",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05968170",
       "title": "TCR\u03b1\u03b2/CD19 Depletion of Stem Cell Grafts for Transplant",
       "status": "WITHDRAWN",
       "last_update": "2025-07-14",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06367114",
       "title": "Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)",
       "status": "UNKNOWN",
       "last_update": "2024-04-19",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06393335",
       "title": "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research",
       "status": "UNKNOWN",
       "last_update": "2024-05-01",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06447987",
       "title": "Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia",
       "status": "SUSPENDED",
       "last_update": "2026-06-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06631040",
       "title": "Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2024-10-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06641024",
       "title": "Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2024-10-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06985498",
       "title": "Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL",
       "status": "SUSPENDED",
       "last_update": "2026-05-29",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07043218",
       "title": "A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-06-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07162571",
       "title": "This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-09-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07166419",
       "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07166549",
       "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-12-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07335094",
       "title": "A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-01-12",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07539610",
       "title": "Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-04-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07754682",
       "title": "Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-10",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD19",
     "blinatumomab",
     "Blincyto",
     "tisagenlecleucel",
     "Kymriah",
     "brexucabtagene",
     "Tecartus",
     "obecabtagene",
     "Aucatzyl"
    ]
   },
   "CD22": {
    "n": 143,
    "n_observational": 8,
    "n_active": 70,
    "n_withdrawn": 9,
    "trials": [
     {
      "nct": "NCT01371630",
      "title": "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02443831",
      "title": "CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02877303",
      "title": "Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03104491",
      "title": "Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03150693",
      "title": "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03739814",
      "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03959085",
      "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04150497",
      "title": "Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)",
      "status": "RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04307576",
      "title": "A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04747912",
      "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05418088",
      "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05442515",
      "title": "CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05645718",
      "title": "Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05674175",
      "title": "Co-administration of CART22-65s and huCART19 for B-ALL",
      "status": "RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05748171",
      "title": "A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940961",
      "title": "Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06081478",
      "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2023-10-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06208735",
      "title": "CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06213636",
      "title": "Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06287229",
      "title": "Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06326008",
      "title": "Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2026-03-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06343090",
      "title": "Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06387121",
      "title": "Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06408194",
      "title": "Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06445803",
      "title": "CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL",
      "status": "RECRUITING",
      "last_update": "2024-06-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533748",
      "title": "Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06554626",
      "title": "Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06559189",
      "title": "CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06659653",
      "title": "Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.",
      "status": "RECRUITING",
      "last_update": "2024-10-26",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06709469",
      "title": "Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults",
      "status": "RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06735495",
      "title": "CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors",
      "status": "RECRUITING",
      "last_update": "2024-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06752785",
      "title": "CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.",
      "status": "RECRUITING",
      "last_update": "2024-12-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06777979",
      "title": "CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06863259",
      "title": "Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06880913",
      "title": "Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL",
      "status": "RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985485",
      "title": "Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07108868",
      "title": "A Phase I Dose Finding Study of MB-CART2219.1",
      "status": "RECRUITING",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07109219",
      "title": "Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07252336",
      "title": "A Multicenter Study of CAR-T Cells in Primary Ph+All",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07328503",
      "title": "CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493161",
      "title": "Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07495631",
      "title": "Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523555",
      "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07575919",
      "title": "Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07575971",
      "title": "Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004086",
      "title": "Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2009-06-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004107",
      "title": "Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2011-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00024115",
      "title": "BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00077493",
      "title": "BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma",
      "status": "SUSPENDED",
      "last_update": "2007-12-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00098839",
      "title": "Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2017-12-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00450944",
      "title": "Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00659425",
      "title": "CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00889408",
      "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01134575",
      "title": "CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01219816",
      "title": "Multi-centric Study",
      "status": "COMPLETED",
      "last_update": "2018-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279707",
      "title": "Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)",
      "status": "UNKNOWN",
      "last_update": "2014-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01354457",
      "title": "Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+",
      "status": "UNKNOWN",
      "last_update": "2014-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01363297",
      "title": "Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01408160",
      "title": "Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2019-09-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01564784",
      "title": "A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-01-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01925131",
      "title": "S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02227108",
      "title": "Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02311998",
      "title": "Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML",
      "status": "COMPLETED",
      "last_update": "2023-07-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02315612",
      "title": "Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02338050",
      "title": "Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2015-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02577094",
      "title": "Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2026-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02588456",
      "title": "Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02650414",
      "title": "CD22 Redirected Autologous T Cells for ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02981628",
      "title": "Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03094611",
      "title": "Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-04-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03185494",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
      "status": "UNKNOWN",
      "last_update": "2019-04-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03233854",
      "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241940",
      "title": "Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03249870",
      "title": "Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL",
      "status": "COMPLETED",
      "last_update": "2026-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03289455",
      "title": "CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03441061",
      "title": "Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03448393",
      "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03460522",
      "title": "Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL",
      "status": "UNKNOWN",
      "last_update": "2022-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03488225",
      "title": "Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03564678",
      "title": "Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610438",
      "title": "Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03614858",
      "title": "CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03620058",
      "title": "CART22 Alone or in Combination With huCART19 for ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03628053",
      "title": "Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2020-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03677596",
      "title": "A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients",
      "status": "COMPLETED",
      "last_update": "2023-11-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03698552",
      "title": "ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-12-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03825731",
      "title": "A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL",
      "status": "UNKNOWN",
      "last_update": "2019-01-31",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03851081",
      "title": "Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2022-01-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03856216",
      "title": "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03913559",
      "title": "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919526",
      "title": "Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor\uff08CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL",
      "status": "COMPLETED",
      "last_update": "2023-12-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03962465",
      "title": "Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL",
      "status": "UNKNOWN",
      "last_update": "2023-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03991884",
      "title": "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03999697",
      "title": "A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2019-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007978",
      "title": "Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2019-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04016129",
      "title": "CAR-T Immunotherapy Targeting CD19- ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04029038",
      "title": "Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04034446",
      "title": "CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04088864",
      "title": "CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04094766",
      "title": "Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2020-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04129099",
      "title": "A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL",
      "status": "UNKNOWN",
      "last_update": "2020-05-28",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04204161",
      "title": "A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04303520",
      "title": "Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL",
      "status": "UNKNOWN",
      "last_update": "2020-03-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04340154",
      "title": "Study of Sequential CAR-T Cell Treating Leukemia Children",
      "status": "TERMINATED",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04340167",
      "title": "Study of Anti-CD22 CAR-T Cells Treating Leukemia Children",
      "status": "COMPLETED",
      "last_update": "2025-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430530",
      "title": "4SCAR-T Therapy Post CD19-targeted Immunotherapy",
      "status": "TERMINATED",
      "last_update": "2026-08-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04499573",
      "title": "Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-02-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04516551",
      "title": "Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT",
      "status": "UNKNOWN",
      "last_update": "2020-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04530565",
      "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546906",
      "title": "Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2020-09-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626726",
      "title": "Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation",
      "status": "UNKNOWN",
      "last_update": "2020-11-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626765",
      "title": "CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2020-11-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04714593",
      "title": "Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-01-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04723901",
      "title": "Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-01-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04740203",
      "title": "Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL",
      "status": "UNKNOWN",
      "last_update": "2021-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04788472",
      "title": "Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL",
      "status": "COMPLETED",
      "last_update": "2024-10-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05016947",
      "title": "Venetoclax Plus Inotuzumab for B-ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05168748",
      "title": "CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2022-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05223686",
      "title": "To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.",
      "status": "UNKNOWN",
      "last_update": "2022-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05225831",
      "title": "Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-02-07",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05292898",
      "title": "A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303792",
      "title": "Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429905",
      "title": "Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia",
      "status": "UNKNOWN",
      "last_update": "2023-03-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05456698",
      "title": "Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05470777",
      "title": "CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05507827",
      "title": "Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05523661",
      "title": "Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients",
      "status": "UNKNOWN",
      "last_update": "2023-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05687032",
      "title": "A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-12-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06009107",
      "title": "A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)",
      "status": "WITHDRAWN",
      "last_update": "2025-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06087419",
      "title": "A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients",
      "status": "UNKNOWN",
      "last_update": "2023-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427330",
      "title": "Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2024-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06438796",
      "title": "Blinatumomab Maintenance After Allo-HSCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06861348",
      "title": "Effectiveness and Safety of InO\u00b1DLI for Relapsed B-ALL/LBL After Allo-HSCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06879262",
      "title": "Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985498",
      "title": "Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL",
      "status": "SUSPENDED",
      "last_update": "2026-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07162571",
      "title": "This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07166419",
      "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07313852",
      "title": "A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07443488",
      "title": "Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476729",
      "title": "International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07643103",
      "title": "Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07770698",
      "title": "A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 68,
     "n_observational": 1,
     "n_active": 33,
     "n_withdrawn": 4,
     "trials": [
      {
       "nct": "NCT02443831",
       "title": "CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia",
       "status": "RECRUITING",
       "last_update": "2026-05-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04150497",
       "title": "Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)",
       "status": "RECRUITING",
       "last_update": "2025-09-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05418088",
       "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-05-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05442515",
       "title": "CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-07-30",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05674175",
       "title": "Co-administration of CART22-65s and huCART19 for B-ALL",
       "status": "RECRUITING",
       "last_update": "2026-03-27",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06081478",
       "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2023-10-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06213636",
       "title": "Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).",
       "status": "RECRUITING",
       "last_update": "2025-08-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06326008",
       "title": "Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial",
       "status": "RECRUITING",
       "last_update": "2026-03-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06408194",
       "title": "Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-09-01",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06445803",
       "title": "CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL",
       "status": "RECRUITING",
       "last_update": "2024-06-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06559189",
       "title": "CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL",
       "status": "RECRUITING",
       "last_update": "2025-11-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06709469",
       "title": "Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults",
       "status": "RECRUITING",
       "last_update": "2025-09-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06735495",
       "title": "CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors",
       "status": "RECRUITING",
       "last_update": "2024-12-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06752785",
       "title": "CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.",
       "status": "RECRUITING",
       "last_update": "2024-12-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06777979",
       "title": "CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2026-05-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06880913",
       "title": "Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL",
       "status": "RECRUITING",
       "last_update": "2026-03-30",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07108868",
       "title": "A Phase I Dose Finding Study of MB-CART2219.1",
       "status": "RECRUITING",
       "last_update": "2025-08-07",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07252336",
       "title": "A Multicenter Study of CAR-T Cells in Primary Ph+All",
       "status": "RECRUITING",
       "last_update": "2025-12-04",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07328503",
       "title": "CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2026-09-11",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07523555",
       "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07575919",
       "title": "Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL",
       "status": "RECRUITING",
       "last_update": "2026-06-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07575971",
       "title": "Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2026-06-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02315612",
       "title": "Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies",
       "status": "COMPLETED",
       "last_update": "2026-04-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02577094",
       "title": "Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia",
       "status": "WITHDRAWN",
       "last_update": "2026-06-24",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02588456",
       "title": "Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia",
       "status": "TERMINATED",
       "last_update": "2023-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02650414",
       "title": "CD22 Redirected Autologous T Cells for ALL",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-07",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03185494",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
       "status": "UNKNOWN",
       "last_update": "2019-04-17",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03233854",
       "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-11-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03241940",
       "title": "Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-30",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03289455",
       "title": "CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)",
       "status": "COMPLETED",
       "last_update": "2021-02-01",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03448393",
       "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies",
       "status": "COMPLETED",
       "last_update": "2025-06-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03614858",
       "title": "CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.",
       "status": "UNKNOWN",
       "last_update": "2023-11-29",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03620058",
       "title": "CART22 Alone or in Combination With huCART19 for ALL",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-10-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03825731",
       "title": "A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL",
       "status": "UNKNOWN",
       "last_update": "2019-01-31",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03919526",
       "title": "Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor\uff08CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL",
       "status": "COMPLETED",
       "last_update": "2023-12-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03999697",
       "title": "A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2019-06-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04007978",
       "title": "Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2019-08-07",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04016129",
       "title": "CAR-T Immunotherapy Targeting CD19- ALL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04029038",
       "title": "Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2023-08-21",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04034446",
       "title": "CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)",
       "status": "TERMINATED",
       "last_update": "2025-06-03",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04088864",
       "title": "CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies",
       "status": "COMPLETED",
       "last_update": "2026-05-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04094766",
       "title": "Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia",
       "status": "WITHDRAWN",
       "last_update": "2020-11-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04129099",
       "title": "A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL",
       "status": "UNKNOWN",
       "last_update": "2020-05-28",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04204161",
       "title": "A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2021-02-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04303520",
       "title": "Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL",
       "status": "UNKNOWN",
       "last_update": "2020-03-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04340154",
       "title": "Study of Sequential CAR-T Cell Treating Leukemia Children",
       "status": "TERMINATED",
       "last_update": "2024-12-05",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04340167",
       "title": "Study of Anti-CD22 CAR-T Cells Treating Leukemia Children",
       "status": "COMPLETED",
       "last_update": "2025-05-18",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04430530",
       "title": "4SCAR-T Therapy Post CD19-targeted Immunotherapy",
       "status": "TERMINATED",
       "last_update": "2026-08-24",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04499573",
       "title": "Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2023-02-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04516551",
       "title": "Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT",
       "status": "UNKNOWN",
       "last_update": "2020-11-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04546906",
       "title": "Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2020-09-14",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04626726",
       "title": "Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation",
       "status": "UNKNOWN",
       "last_update": "2020-11-13",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04626765",
       "title": "CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2020-11-13",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04714593",
       "title": "Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-01-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04723901",
       "title": "Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-01-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04740203",
       "title": "Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL",
       "status": "UNKNOWN",
       "last_update": "2021-02-05",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04788472",
       "title": "Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL",
       "status": "COMPLETED",
       "last_update": "2024-10-17",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05168748",
       "title": "CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia",
       "status": "WITHDRAWN",
       "last_update": "2022-12-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05223686",
       "title": "To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.",
       "status": "UNKNOWN",
       "last_update": "2022-02-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05225831",
       "title": "Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2022-02-07",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05429905",
       "title": "Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia",
       "status": "UNKNOWN",
       "last_update": "2023-03-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05470777",
       "title": "CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-09-02",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05507827",
       "title": "Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05523661",
       "title": "Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients",
       "status": "UNKNOWN",
       "last_update": "2023-11-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06879262",
       "title": "Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-01-06",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06985498",
       "title": "Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL",
       "status": "SUSPENDED",
       "last_update": "2026-05-29",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07162571",
       "title": "This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-09-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07166419",
       "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD22",
     "inotuzumab",
     "Besponsa"
    ]
   },
   "CD7": {
    "n": 45,
    "n_observational": 1,
    "n_active": 24,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT05043571",
      "title": "CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia",
      "status": "RECRUITING",
      "last_update": "2021-09-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620680",
      "title": "CD7 CAR-T Cells in T-cell Lymphoma/Leukemia",
      "status": "RECRUITING",
      "last_update": "2022-11-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05626400",
      "title": "Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL",
      "status": "RECRUITING",
      "last_update": "2022-11-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06064903",
      "title": "CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06136364",
      "title": "CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study",
      "status": "RECRUITING",
      "last_update": "2023-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06316427",
      "title": "Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-11-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06420076",
      "title": "Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells",
      "status": "RECRUITING",
      "last_update": "2024-11-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06514794",
      "title": "A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06934382",
      "title": "Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07109518",
      "title": "uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07153068",
      "title": "SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-12-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07188610",
      "title": "PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07220993",
      "title": "Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07280494",
      "title": "To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT",
      "status": "RECRUITING",
      "last_update": "2025-12-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523555",
      "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02742727",
      "title": "CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03690011",
      "title": "Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04004637",
      "title": "CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2020-09-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04033302",
      "title": "Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04480788",
      "title": "CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study",
      "status": "UNKNOWN",
      "last_update": "2021-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04572308",
      "title": "Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells",
      "status": "COMPLETED",
      "last_update": "2021-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04620655",
      "title": "RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL",
      "status": "UNKNOWN",
      "last_update": "2020-11-09",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04689659",
      "title": "Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04762485",
      "title": "Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-06-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04785833",
      "title": "CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-03-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04860817",
      "title": "A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL",
      "status": "WITHDRAWN",
      "last_update": "2022-11-29",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916860",
      "title": "Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04934774",
      "title": "Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances",
      "status": "UNKNOWN",
      "last_update": "2021-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04984356",
      "title": "A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL",
      "status": "COMPLETED",
      "last_update": "2025-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05127135",
      "title": "Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2021-11-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05212584",
      "title": "CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05290155",
      "title": "Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-06-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05377827",
      "title": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies",
      "status": "SUSPENDED",
      "last_update": "2026-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05398614",
      "title": "SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies",
      "status": "UNKNOWN",
      "last_update": "2022-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05513612",
      "title": "Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2023-03-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05716113",
      "title": "CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL",
      "status": "COMPLETED",
      "last_update": "2024-11-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05885464",
      "title": "A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05907603",
      "title": "Research Development\uff08RD\uff0913-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7\uff08CD7\uff09+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)",
      "status": "COMPLETED",
      "last_update": "2024-11-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05909527",
      "title": "A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2026-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05995028",
      "title": "Universal 4SCAR7U Targeting CD7-positive Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06849401",
      "title": "The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-05-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07244380",
      "title": "Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476027",
      "title": "Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623681",
      "title": "Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07784309",
      "title": "A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 37,
     "n_observational": 1,
     "n_active": 18,
     "n_withdrawn": 3,
     "trials": [
      {
       "nct": "NCT05043571",
       "title": "CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia",
       "status": "RECRUITING",
       "last_update": "2021-09-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05620680",
       "title": "CD7 CAR-T Cells in T-cell Lymphoma/Leukemia",
       "status": "RECRUITING",
       "last_update": "2022-11-17",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05626400",
       "title": "Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL",
       "status": "RECRUITING",
       "last_update": "2022-11-25",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06064903",
       "title": "CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL",
       "status": "RECRUITING",
       "last_update": "2025-12-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06136364",
       "title": "CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study",
       "status": "RECRUITING",
       "last_update": "2023-11-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06316427",
       "title": "Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2025-11-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06420076",
       "title": "Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells",
       "status": "RECRUITING",
       "last_update": "2024-11-12",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06514794",
       "title": "A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)",
       "status": "RECRUITING",
       "last_update": "2026-09-03",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06934382",
       "title": "Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-07-07",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07109518",
       "title": "uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies",
       "status": "RECRUITING",
       "last_update": "2025-09-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07153068",
       "title": "SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies",
       "status": "RECRUITING",
       "last_update": "2025-12-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07220993",
       "title": "Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells",
       "status": "RECRUITING",
       "last_update": "2026-05-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07280494",
       "title": "To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT",
       "status": "RECRUITING",
       "last_update": "2025-12-12",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07523555",
       "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02742727",
       "title": "CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2016-12-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03690011",
       "title": "Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-16",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04004637",
       "title": "CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia",
       "status": "UNKNOWN",
       "last_update": "2020-09-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04033302",
       "title": "Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04480788",
       "title": "CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study",
       "status": "UNKNOWN",
       "last_update": "2021-01-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04572308",
       "title": "Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells",
       "status": "COMPLETED",
       "last_update": "2021-06-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04689659",
       "title": "Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma",
       "status": "COMPLETED",
       "last_update": "2025-05-18",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04762485",
       "title": "Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-06-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04785833",
       "title": "CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-03-08",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04860817",
       "title": "A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL",
       "status": "WITHDRAWN",
       "last_update": "2022-11-29",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04916860",
       "title": "Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2023-03-31",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04934774",
       "title": "Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances",
       "status": "UNKNOWN",
       "last_update": "2021-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04984356",
       "title": "A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL",
       "status": "COMPLETED",
       "last_update": "2025-09-30",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05127135",
       "title": "Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2021-11-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05212584",
       "title": "CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2022-07-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05290155",
       "title": "Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies",
       "status": "COMPLETED",
       "last_update": "2025-06-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05377827",
       "title": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies",
       "status": "SUSPENDED",
       "last_update": "2026-07-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05513612",
       "title": "Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies",
       "status": "WITHDRAWN",
       "last_update": "2023-03-01",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05716113",
       "title": "CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL",
       "status": "COMPLETED",
       "last_update": "2024-11-21",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05907603",
       "title": "Research Development\uff08RD\uff0913-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7\uff08CD7\uff09+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)",
       "status": "COMPLETED",
       "last_update": "2024-11-21",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05909527",
       "title": "A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2026-03-17",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07244380",
       "title": "Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-11-24",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07476027",
       "title": "Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-03-17",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD7"
    ]
   },
   "CD38": {
    "n": 22,
    "n_observational": 0,
    "n_active": 11,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT04972942",
      "title": "Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05289687",
      "title": "Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06287944",
      "title": "225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06398457",
      "title": "Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies",
      "status": "RECRUITING",
      "last_update": "2025-09-26",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06648889",
      "title": "Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07021677",
      "title": "Use of a New Medicine \"Daratumumab\" to Treat Left-over Cancer in a Blood Cancer Called \"T Acute Lymphoblastic Leukemia\"",
      "status": "RECRUITING",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07513129",
      "title": "Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523555",
      "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02999633",
      "title": "Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03207542",
      "title": "Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "WITHDRAWN",
      "last_update": "2018-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03384654",
      "title": "A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03754764",
      "title": "A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy",
      "status": "UNKNOWN",
      "last_update": "2018-12-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03860844",
      "title": "Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04016129",
      "title": "CAR-T Immunotherapy Targeting CD19- ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430530",
      "title": "4SCAR-T Therapy Post CD19-targeted Immunotherapy",
      "status": "TERMINATED",
      "last_update": "2026-08-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04762485",
      "title": "Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia",
      "status": "UNKNOWN",
      "last_update": "2021-06-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05038644",
      "title": "XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05519527",
      "title": "STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis",
      "status": "WITHDRAWN",
      "last_update": "2023-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253637",
      "title": "Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06570915",
      "title": "Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy",
      "status": "WITHDRAWN",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07072585",
      "title": "Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07585734",
      "title": "Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2026-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 5,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT07523555",
       "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03754764",
       "title": "A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy",
       "status": "UNKNOWN",
       "last_update": "2018-12-07",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04016129",
       "title": "CAR-T Immunotherapy Targeting CD19- ALL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04430530",
       "title": "4SCAR-T Therapy Post CD19-targeted Immunotherapy",
       "status": "TERMINATED",
       "last_update": "2026-08-24",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04762485",
       "title": "Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia",
       "status": "UNKNOWN",
       "last_update": "2021-06-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD38",
     "daratumumab"
    ]
   },
   "BCR-ABL1": {
    "n": 201,
    "n_observational": 30,
    "n_active": 51,
    "n_withdrawn": 7,
    "trials": [
     {
      "nct": "NCT03263572",
      "title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03595917",
      "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",
      "status": "RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03739814",
      "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03934372",
      "title": "Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04179929",
      "title": "Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults",
      "status": "RECRUITING",
      "last_update": "2022-02-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04307576",
      "title": "A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603872",
      "title": "CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2020-10-28",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04747912",
      "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05751044",
      "title": "HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06051409",
      "title": "A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)",
      "status": "RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06061094",
      "title": "Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT",
      "status": "RECRUITING",
      "last_update": "2025-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06124157",
      "title": "A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06207123",
      "title": "A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)",
      "status": "RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06257394",
      "title": "Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06308588",
      "title": "Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06336395",
      "title": "Ma-Spore ALL 2020 Study",
      "status": "RECRUITING",
      "last_update": "2024-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06390319",
      "title": "Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533748",
      "title": "Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06855810",
      "title": "Newly-diagnosed Pediatric T-cell ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2025-08-26",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06860269",
      "title": "A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985485",
      "title": "Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07040982",
      "title": "Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07152041",
      "title": "Newly-diagnosed Pediatric Ph-positive B-ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07203352",
      "title": "Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07224100",
      "title": "Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07250087",
      "title": "Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL",
      "status": "RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387926",
      "title": "Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002514",
      "title": "Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission",
      "status": "COMPLETED",
      "last_update": "2023-06-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004932",
      "title": "STI571 in Treating Patients With Recurrent Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015860",
      "title": "STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022737",
      "title": "Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025415",
      "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction",
      "status": "COMPLETED",
      "last_update": "2013-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036738",
      "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "COMPLETED",
      "last_update": "2020-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00038610",
      "title": "Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039377",
      "title": "Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049569",
      "title": "Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-10-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00053196",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00061945",
      "title": "Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064285",
      "title": "Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2010-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00081133",
      "title": "Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101595",
      "title": "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00103701",
      "title": "BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00109707",
      "title": "A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123487",
      "title": "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML",
      "status": "COMPLETED",
      "last_update": "2014-11-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00130195",
      "title": "Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2008-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00131027",
      "title": "High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)",
      "status": "UNKNOWN",
      "last_update": "2008-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00131053",
      "title": "Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)",
      "status": "UNKNOWN",
      "last_update": "2008-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00137111",
      "title": "Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00149136",
      "title": "Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.",
      "status": "UNKNOWN",
      "last_update": "2007-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00154349",
      "title": "Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00167180",
      "title": "Post Transplant Donor Lymphocyte Infusion",
      "status": "TERMINATED",
      "last_update": "2019-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171223",
      "title": "An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171249",
      "title": "An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00199186",
      "title": "Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "UNKNOWN",
      "last_update": "2007-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244829",
      "title": "Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00245037",
      "title": "Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00281879",
      "title": "Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2017-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00287105",
      "title": "Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children",
      "status": "COMPLETED",
      "last_update": "2023-05-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00293384",
      "title": "Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2016-03-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00298987",
      "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2010-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00316953",
      "title": "Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2013-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324324",
      "title": "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-05-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00327678",
      "title": "Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults",
      "status": "COMPLETED",
      "last_update": "2016-06-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00337454",
      "title": "Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00345826",
      "title": "Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00349518",
      "title": "Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00352677",
      "title": "Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2009-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00376467",
      "title": "STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-02-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00378781",
      "title": "Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection",
      "status": "WITHDRAWN",
      "last_update": "2012-02-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00384228",
      "title": "A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00388895",
      "title": "Glivec in Ph Positive Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2008-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390793",
      "title": "Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00391989",
      "title": "Treatment of Adult Ph+ LAL With BMS-354825",
      "status": "COMPLETED",
      "last_update": "2017-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00424242",
      "title": "Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases",
      "status": "COMPLETED",
      "last_update": "2021-09-08",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00458848",
      "title": "Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00476190",
      "title": "ALL Adult Consortium Trial: Adult ALL Trial",
      "status": "COMPLETED",
      "last_update": "2025-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00500006",
      "title": "A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)",
      "status": "TERMINATED",
      "last_update": "2015-01-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00529763",
      "title": "Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects",
      "status": "COMPLETED",
      "last_update": "2023-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00549848",
      "title": "Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-08-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00589563",
      "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer",
      "status": "COMPLETED",
      "last_update": "2014-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00608361",
      "title": "Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2015-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00618501",
      "title": "Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00666211",
      "title": "Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain",
      "status": "COMPLETED",
      "last_update": "2012-09-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691015",
      "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2017-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00702403",
      "title": "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML",
      "status": "COMPLETED",
      "last_update": "2017-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00716911",
      "title": "Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2015-06-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720109",
      "title": "Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-04-13",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00755040",
      "title": "Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder",
      "status": "COMPLETED",
      "last_update": "2017-03-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00763763",
      "title": "Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive",
      "status": "COMPLETED",
      "last_update": "2011-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00782145",
      "title": "A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families",
      "status": "COMPLETED",
      "last_update": "2011-07-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00787761",
      "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer",
      "status": "COMPLETED",
      "last_update": "2012-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00792948",
      "title": "Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00816283",
      "title": "Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2012-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00852709",
      "title": "Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias",
      "status": "TERMINATED",
      "last_update": "2018-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00860535",
      "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)",
      "status": "TERMINATED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00882206",
      "title": "Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00905398",
      "title": "Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2015-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00935090",
      "title": "3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": null,
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00940524",
      "title": "Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00946283",
      "title": "Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome",
      "status": "TERMINATED",
      "last_update": "2017-02-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00951626",
      "title": "A Standardized Nursing Intervention Protocol for HCT Patients",
      "status": "COMPLETED",
      "last_update": "2015-06-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00952185",
      "title": "Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers",
      "status": "TERMINATED",
      "last_update": "2015-06-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00973752",
      "title": "Treatment of Older Adults With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00978731",
      "title": "Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study",
      "status": "COMPLETED",
      "last_update": "2011-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00982488",
      "title": "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00990249",
      "title": "Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2018-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01004497",
      "title": "First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL",
      "status": "COMPLETED",
      "last_update": "2015-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01005758",
      "title": "Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01005914",
      "title": "Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01025505",
      "title": "Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study",
      "status": "COMPLETED",
      "last_update": "2022-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030718",
      "title": "Rollover Study of BMS-354825 in Patients With CML and Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2010-12-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01066468",
      "title": "Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec\u00ae Indicated Hematological Disorders.",
      "status": "TERMINATED",
      "last_update": "2012-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01077544",
      "title": "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01085617",
      "title": "Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": null,
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101412",
      "title": "Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2013-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01116232",
      "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2019-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01158118",
      "title": "Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors",
      "status": "COMPLETED",
      "last_update": "2017-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207440",
      "title": "Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01222013",
      "title": "Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)",
      "status": "SUSPENDED",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01256398",
      "title": "Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279473",
      "title": "Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01310010",
      "title": "Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01312818",
      "title": "Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01319981",
      "title": "Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01376427",
      "title": "Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years",
      "status": "UNKNOWN",
      "last_update": "2022-06-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01383447",
      "title": "Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01424982",
      "title": "Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01429610",
      "title": "Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2018-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01460160",
      "title": "Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01491763",
      "title": "Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE",
      "status": "UNKNOWN",
      "last_update": "2022-01-19",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01528085",
      "title": "Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01609816",
      "title": "Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2020-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01616238",
      "title": "A Study for Older Adults With Acute Lymphoblastic Leukaemia",
      "status": "COMPLETED",
      "last_update": "2023-08-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01641107",
      "title": "Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.",
      "status": "COMPLETED",
      "last_update": "2021-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01643603",
      "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2020-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01665001",
      "title": "Personalized Therapy of Precursor Lymphoid Neoplasms",
      "status": "UNKNOWN",
      "last_update": "2012-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01667133",
      "title": "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2022-06-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01724879",
      "title": "Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)",
      "status": "COMPLETED",
      "last_update": "2022-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01883219",
      "title": "TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02003222",
      "title": "Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02043587",
      "title": "Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-05-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02143414",
      "title": "Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02272777",
      "title": "A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02352558",
      "title": "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420717",
      "title": "Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02494882",
      "title": "Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02523976",
      "title": "Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02538926",
      "title": "Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2018-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02551718",
      "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611492",
      "title": "A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults",
      "status": "UNKNOWN",
      "last_update": "2019-10-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02629692",
      "title": "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to \u22653 Prior CML Therapies",
      "status": "TERMINATED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02690922",
      "title": "Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients",
      "status": "UNKNOWN",
      "last_update": "2016-02-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02744768",
      "title": "D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2018-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02776605",
      "title": "Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02779283",
      "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02815059",
      "title": "Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",
      "status": "WITHDRAWN",
      "last_update": "2018-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02819804",
      "title": "Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2020-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02881086",
      "title": "Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment",
      "status": "COMPLETED",
      "last_update": "2025-12-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02883049",
      "title": "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations",
      "status": "COMPLETED",
      "last_update": "2026-06-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02888990",
      "title": "Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02894645",
      "title": "Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study",
      "status": "UNKNOWN",
      "last_update": "2016-09-30",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03007147",
      "title": "Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03020030",
      "title": "Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03023046",
      "title": "Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03117751",
      "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03147612",
      "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03414450",
      "title": "Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2018-10-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03480438",
      "title": "Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab",
      "status": "COMPLETED",
      "last_update": "2025-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03515200",
      "title": "Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2020-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03564470",
      "title": "Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL",
      "status": "UNKNOWN",
      "last_update": "2022-07-01",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03576547",
      "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03589326",
      "title": "A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03624530",
      "title": "Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants",
      "status": "UNKNOWN",
      "last_update": "2018-08-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04233346",
      "title": "The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04329325",
      "title": "Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04475731",
      "title": "Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04501614",
      "title": "A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04530565",
      "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04554459",
      "title": "Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL",
      "status": "TERMINATED",
      "last_update": "2024-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04688983",
      "title": "Study in Adult Ph-positive ALL",
      "status": "UNKNOWN",
      "last_update": "2020-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04722848",
      "title": "Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04845035",
      "title": "Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2024-02-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04872790",
      "title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04996160",
      "title": "Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024357",
      "title": "A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL",
      "status": "UNKNOWN",
      "last_update": "2021-10-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05026229",
      "title": "A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL",
      "status": "UNKNOWN",
      "last_update": "2021-10-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05071482",
      "title": "Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL",
      "status": "TERMINATED",
      "last_update": "2025-05-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05192889",
      "title": "Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05268003",
      "title": "A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05306301",
      "title": "Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05523661",
      "title": "Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients",
      "status": "UNKNOWN",
      "last_update": "2023-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05594784",
      "title": "Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2025-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05993949",
      "title": "Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06773936",
      "title": "Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07301424",
      "title": "Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07614022",
      "title": "A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 4,
     "n_observational": 2,
     "n_active": 2,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04603872",
       "title": "CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies",
       "status": "RECRUITING",
       "last_update": "2020-10-28",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07250087",
       "title": "Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL",
       "status": "RECRUITING",
       "last_update": "2026-03-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00167180",
       "title": "Post Transplant Donor Lymphocyte Infusion",
       "status": "TERMINATED",
       "last_update": "2019-07-30",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05523661",
       "title": "Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients",
       "status": "UNKNOWN",
       "last_update": "2023-11-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "BCR-ABL",
     "imatinib",
     "dasatinib",
     "ponatinib",
     "asciminib"
    ]
   },
   "CD3": {
    "n": 119,
    "n_observational": 1,
    "n_active": 59,
    "n_withdrawn": 6,
    "trials": [
     {
      "nct": "NCT02877303",
      "title": "Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03263572",
      "title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03643276",
      "title": "Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017",
      "status": "RECRUITING",
      "last_update": "2025-04-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03739814",
      "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03938987",
      "title": "Anti-CD19, Dual Co-stimulatory (4-1BB, CD3\u03b6) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03959085",
      "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04544592",
      "title": "UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546399",
      "title": "A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800210",
      "title": "Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06081478",
      "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2023-10-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06124157",
      "title": "A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06144606",
      "title": "Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06220487",
      "title": "A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL",
      "status": "RECRUITING",
      "last_update": "2024-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06227026",
      "title": "Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06317662",
      "title": "Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06387121",
      "title": "Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533579",
      "title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06554626",
      "title": "Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06559189",
      "title": "CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06735495",
      "title": "CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors",
      "status": "RECRUITING",
      "last_update": "2024-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06777979",
      "title": "CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06890494",
      "title": "Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985485",
      "title": "Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07059156",
      "title": "Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL",
      "status": "RECRUITING",
      "last_update": "2025-07-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07105579",
      "title": "Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07133997",
      "title": "Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227584",
      "title": "ALL Backbone in AYAs",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07366801",
      "title": "Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-01-26",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07471789",
      "title": "Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493161",
      "title": "Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07648264",
      "title": "Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07677878",
      "title": "Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07695012",
      "title": "CAR-T Cell Therapy for ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005852",
      "title": "Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant",
      "status": "TERMINATED",
      "last_update": "2012-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006009",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00014560",
      "title": "Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2018-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00079391",
      "title": "Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies",
      "status": "COMPLETED",
      "last_update": "2015-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00096161",
      "title": "Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2020-01-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00145626",
      "title": "HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00161187",
      "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor",
      "status": "COMPLETED",
      "last_update": "2015-11-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00167180",
      "title": "Post Transplant Donor Lymphocyte Infusion",
      "status": "TERMINATED",
      "last_update": "2019-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244946",
      "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00450983",
      "title": "Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases",
      "status": "TERMINATED",
      "last_update": "2017-05-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00521261",
      "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2014-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00558675",
      "title": "A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy",
      "status": "COMPLETED",
      "last_update": "2020-01-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00560794",
      "title": "Phase II Study of the BiTE\u00ae Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2015-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00674427",
      "title": "Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2020-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00741455",
      "title": "Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-11-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00816413",
      "title": "Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00859586",
      "title": "Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2020-10-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00889408",
      "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00961142",
      "title": "Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01044069",
      "title": "Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01050764",
      "title": "Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells",
      "status": "TERMINATED",
      "last_update": "2018-06-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01163201",
      "title": "T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2017-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01175785",
      "title": "Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2019-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207388",
      "title": "Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01209286",
      "title": "Study of the BiTE\u00ae Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2017-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01386619",
      "title": "NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)",
      "status": "COMPLETED",
      "last_update": "2024-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01423500",
      "title": "ALL-SCT BFM International- HSCT in Children and Adolescents With ALL",
      "status": "UNKNOWN",
      "last_update": "2015-06-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01423747",
      "title": "Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia",
      "status": "UNKNOWN",
      "last_update": "2015-06-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01466179",
      "title": "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01471782",
      "title": "Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-02-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01517035",
      "title": "Improving Blood Stem Cell Collection and Transplant Procedures",
      "status": "COMPLETED",
      "last_update": "2018-07-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01660607",
      "title": "Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell",
      "status": "COMPLETED",
      "last_update": "2025-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01685606",
      "title": "Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01700946",
      "title": "Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02003222",
      "title": "Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02007811",
      "title": "Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination",
      "status": "UNKNOWN",
      "last_update": "2014-03-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02101853",
      "title": "Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02143414",
      "title": "Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02393859",
      "title": "Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2026-06-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02454270",
      "title": "A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2018-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02458014",
      "title": "Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease",
      "status": "COMPLETED",
      "last_update": "2025-09-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02646839",
      "title": "KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2025-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02744768",
      "title": "D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2018-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02790515",
      "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02848911",
      "title": "Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL",
      "status": "TERMINATED",
      "last_update": "2019-06-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02879695",
      "title": "Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02997761",
      "title": "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03147612",
      "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03281551",
      "title": "Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2017-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03512405",
      "title": "Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03518112",
      "title": "Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03523429",
      "title": "PETHEMA-BLIN-01/PET069014 (BLIN-01)",
      "status": "TERMINATED",
      "last_update": "2022-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03574168",
      "title": "CD19-CAR-T Cells in Patients With R/R B-ALL",
      "status": "UNKNOWN",
      "last_update": "2018-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03628053",
      "title": "Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2020-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03671460",
      "title": "CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.",
      "status": "UNKNOWN",
      "last_update": "2018-09-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03739606",
      "title": "Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer",
      "status": "WITHDRAWN",
      "last_update": "2020-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03751709",
      "title": "Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL",
      "status": "COMPLETED",
      "last_update": "2025-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03825731",
      "title": "A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL",
      "status": "UNKNOWN",
      "last_update": "2019-01-31",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849651",
      "title": "TCR\u03b1\u03b2-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03914625",
      "title": "A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919526",
      "title": "Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor\uff08CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL",
      "status": "COMPLETED",
      "last_update": "2023-12-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04034446",
      "title": "CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04303520",
      "title": "Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL",
      "status": "UNKNOWN",
      "last_update": "2020-03-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04499573",
      "title": "Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-02-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04530565",
      "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04601584",
      "title": "GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL",
      "status": "UNKNOWN",
      "last_update": "2024-03-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04681105",
      "title": "Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04722848",
      "title": "Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04872790",
      "title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05038644",
      "title": "XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429905",
      "title": "Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia",
      "status": "UNKNOWN",
      "last_update": "2023-03-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05460533",
      "title": "A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05523661",
      "title": "Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients",
      "status": "UNKNOWN",
      "last_update": "2023-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05779930",
      "title": "Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05968170",
      "title": "TCR\u03b1\u03b2/CD19 Depletion of Stem Cell Grafts for Transplant",
      "status": "WITHDRAWN",
      "last_update": "2025-07-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06503094",
      "title": "CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06861348",
      "title": "Effectiveness and Safety of InO\u00b1DLI for Relapsed B-ALL/LBL After Allo-HSCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985498",
      "title": "Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL",
      "status": "SUSPENDED",
      "last_update": "2026-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07166549",
      "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07254793",
      "title": "Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07371533",
      "title": "Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476729",
      "title": "International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07499128",
      "title": "Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-06-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07636564",
      "title": "Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07643103",
      "title": "Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 38,
     "n_observational": 0,
     "n_active": 18,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT03938987",
       "title": "Anti-CD19, Dual Co-stimulatory (4-1BB, CD3\u03b6) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)",
       "status": "RECRUITING",
       "last_update": "2026-02-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04544592",
       "title": "UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",
       "status": "RECRUITING",
       "last_update": "2026-04-20",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06081478",
       "title": "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2023-10-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06227026",
       "title": "Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06559189",
       "title": "CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL",
       "status": "RECRUITING",
       "last_update": "2025-11-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06735495",
       "title": "CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors",
       "status": "RECRUITING",
       "last_update": "2024-12-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06777979",
       "title": "CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2026-05-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07105579",
       "title": "Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2025-08-06",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07366801",
       "title": "Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-01-26",
       "phase": "PHASE2/PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07471789",
       "title": "Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).",
       "status": "RECRUITING",
       "last_update": "2026-03-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07648264",
       "title": "Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies",
       "status": "RECRUITING",
       "last_update": "2026-09-09",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07695012",
       "title": "CAR-T Cell Therapy for ALL",
       "status": "RECRUITING",
       "last_update": "2026-07-10",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00096161",
       "title": "Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant",
       "status": "COMPLETED",
       "last_update": "2020-01-31",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00161187",
       "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor",
       "status": "COMPLETED",
       "last_update": "2015-11-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00167180",
       "title": "Post Transplant Donor Lymphocyte Infusion",
       "status": "TERMINATED",
       "last_update": "2019-07-30",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00521261",
       "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2014-03-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00674427",
       "title": "Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant",
       "status": "TERMINATED",
       "last_update": "2020-08-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00859586",
       "title": "Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation",
       "status": "COMPLETED",
       "last_update": "2020-10-27",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01044069",
       "title": "Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-09-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01050764",
       "title": "Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells",
       "status": "TERMINATED",
       "last_update": "2018-06-27",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01685606",
       "title": "Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma",
       "status": "TERMINATED",
       "last_update": "2022-03-04",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02790515",
       "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-08-12",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03574168",
       "title": "CD19-CAR-T Cells in Patients With R/R B-ALL",
       "status": "UNKNOWN",
       "last_update": "2018-06-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03671460",
       "title": "CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.",
       "status": "UNKNOWN",
       "last_update": "2018-09-14",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03751709",
       "title": "Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL",
       "status": "COMPLETED",
       "last_update": "2025-02-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03825731",
       "title": "A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL",
       "status": "UNKNOWN",
       "last_update": "2019-01-31",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03849651",
       "title": "TCR\u03b1\u03b2-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-22",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03919526",
       "title": "Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor\uff08CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL",
       "status": "COMPLETED",
       "last_update": "2023-12-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04034446",
       "title": "CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)",
       "status": "TERMINATED",
       "last_update": "2025-06-03",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04303520",
       "title": "Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL",
       "status": "UNKNOWN",
       "last_update": "2020-03-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04499573",
       "title": "Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2023-02-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05429905",
       "title": "Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia",
       "status": "UNKNOWN",
       "last_update": "2023-03-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05523661",
       "title": "Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients",
       "status": "UNKNOWN",
       "last_update": "2023-11-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05779930",
       "title": "Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-08-15",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05968170",
       "title": "TCR\u03b1\u03b2/CD19 Depletion of Stem Cell Grafts for Transplant",
       "status": "WITHDRAWN",
       "last_update": "2025-07-14",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06503094",
       "title": "CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors",
       "status": "UNKNOWN",
       "last_update": "2024-07-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06985498",
       "title": "Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL",
       "status": "SUSPENDED",
       "last_update": "2026-05-29",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07166549",
       "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-12-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD3",
     "bispecific"
    ]
   },
   "CD20": {
    "n": 163,
    "n_observational": 2,
    "n_active": 39,
    "n_withdrawn": 7,
    "trials": [
     {
      "nct": "NCT01371630",
      "title": "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02727803",
      "title": "Personalized NK Cell Therapy in CBT",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02877303",
      "title": "Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136146",
      "title": "Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03150693",
      "title": "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571321",
      "title": "Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04318678",
      "title": "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04920968",
      "title": "Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 \"OVERALL\"",
      "status": "RECRUITING",
      "last_update": "2025-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05418088",
      "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05581030",
      "title": "CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)",
      "status": "RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05618041",
      "title": "The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-06-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05645718",
      "title": "Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05735717",
      "title": "MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06336395",
      "title": "Ma-Spore ALL 2020 Study",
      "status": "RECRUITING",
      "last_update": "2024-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06364423",
      "title": "Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06410833",
      "title": "Belimumab After Rituximab in Resistant Primary Juvenile SS",
      "status": "RECRUITING",
      "last_update": "2024-05-16",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06508775",
      "title": "Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies",
      "status": "RECRUITING",
      "last_update": "2025-11-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06738368",
      "title": "Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06918431",
      "title": "Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07039877",
      "title": "Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07224100",
      "title": "Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07470073",
      "title": "A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523555",
      "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002663",
      "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003397",
      "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003874",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003963",
      "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004260",
      "title": "Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2011-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005601",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00010192",
      "title": "Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028665",
      "title": "Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2010-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039130",
      "title": "Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00040950",
      "title": "Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052936",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00057811",
      "title": "Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058292",
      "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058461",
      "title": "Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2013-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062296",
      "title": "Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00067002",
      "title": "Randomized Double Cord Blood Transplant Study",
      "status": "COMPLETED",
      "last_update": "2019-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00072514",
      "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073918",
      "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073931",
      "title": "Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080886",
      "title": "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080925",
      "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00087009",
      "title": "Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2013-03-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110071",
      "title": "Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119392",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00133991",
      "title": "Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2018-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00143559",
      "title": "Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2009-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00145613",
      "title": "Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2009-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00176475",
      "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
      "status": "TERMINATED",
      "last_update": "2013-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00198978",
      "title": "German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-03-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00199004",
      "title": "Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab",
      "status": "COMPLETED",
      "last_update": "2010-08-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00199082",
      "title": "Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults",
      "status": "COMPLETED",
      "last_update": "2022-08-19",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00238368",
      "title": "Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244946",
      "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00274794",
      "title": "VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL",
      "status": "COMPLETED",
      "last_update": "2011-03-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00288067",
      "title": "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324779",
      "title": "Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00327678",
      "title": "Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults",
      "status": "COMPLETED",
      "last_update": "2016-06-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00388193",
      "title": "Rituximab Combined With Chemotherapy in Burkitt's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00392691",
      "title": "Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00410982",
      "title": "Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2016-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00416923",
      "title": "Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00427557",
      "title": "Cellular Therapy With Cord Blood Cells",
      "status": "COMPLETED",
      "last_update": "2012-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00427791",
      "title": "Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00452374",
      "title": "Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL",
      "status": "COMPLETED",
      "last_update": "2011-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00498316",
      "title": "Cord Blood Expansion on Mesenchymal Stem Cells",
      "status": "COMPLETED",
      "last_update": "2020-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00521261",
      "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2014-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00601718",
      "title": "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617929",
      "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00625729",
      "title": "Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00671658",
      "title": "Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691015",
      "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2017-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691652",
      "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00726700",
      "title": "Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00797810",
      "title": "Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults",
      "status": "UNKNOWN",
      "last_update": "2009-09-15",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00801580",
      "title": "My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia",
      "status": "UNKNOWN",
      "last_update": "2009-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00818961",
      "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2013-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00844298",
      "title": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00863369",
      "title": "Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867529",
      "title": "Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00905034",
      "title": "Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage",
      "status": "COMPLETED",
      "last_update": "2015-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01010217",
      "title": "Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide",
      "status": "COMPLETED",
      "last_update": "2020-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01044745",
      "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2023-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01045928",
      "title": "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01085617",
      "title": "Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": null,
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01116232",
      "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2019-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01134575",
      "title": "CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01184885",
      "title": "A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2025-05-04",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01230788",
      "title": "Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2014-12-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279707",
      "title": "Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)",
      "status": "UNKNOWN",
      "last_update": "2014-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01290120",
      "title": "Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01307592",
      "title": "Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01319981",
      "title": "Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01326702",
      "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01358253",
      "title": "Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-05-20",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01362452",
      "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells",
      "status": "COMPLETED",
      "last_update": "2017-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01363128",
      "title": "Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01419795",
      "title": "Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01424982",
      "title": "Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01429610",
      "title": "Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2018-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01471067",
      "title": "Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01520922",
      "title": "Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)",
      "status": "COMPLETED",
      "last_update": "2017-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01619761",
      "title": "NK Cells in Cord Blood Transplantation",
      "status": "UNKNOWN",
      "last_update": "2020-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01670084",
      "title": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01700946",
      "title": "Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01735604",
      "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy",
      "status": "UNKNOWN",
      "last_update": "2015-09-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01805037",
      "title": "Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas",
      "status": "TERMINATED",
      "last_update": "2021-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01842672",
      "title": "Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-10-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02003222",
      "title": "Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02043587",
      "title": "Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-05-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02168907",
      "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02199184",
      "title": "Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2024-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02259348",
      "title": "Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation",
      "status": "TERMINATED",
      "last_update": "2017-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02265731",
      "title": "Study Evaluating Venetoclax in Subjects With Hematological Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-08-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02281279",
      "title": "Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02293109",
      "title": "Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02419469",
      "title": "Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420717",
      "title": "Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02538926",
      "title": "Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2018-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02779283",
      "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02790515",
      "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02881086",
      "title": "Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment",
      "status": "COMPLETED",
      "last_update": "2025-12-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02960646",
      "title": "Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03023046",
      "title": "Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03096782",
      "title": "Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03097770",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
      "status": "COMPLETED",
      "last_update": "2020-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03147612",
      "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03236857",
      "title": "A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03488225",
      "title": "Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03518112",
      "title": "Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03576547",
      "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03615105",
      "title": "Donor Stem Cell Transplantation Using \u03b1/\u03b2+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors",
      "status": "TERMINATED",
      "last_update": "2025-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03808610",
      "title": "Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03856216",
      "title": "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04000698",
      "title": "Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias",
      "status": "UNKNOWN",
      "last_update": "2020-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04016129",
      "title": "CAR-T Immunotherapy Targeting CD19- ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04049383",
      "title": "CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL",
      "status": "TERMINATED",
      "last_update": "2026-01-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04224571",
      "title": "CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children",
      "status": "COMPLETED",
      "last_update": "2023-08-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430530",
      "title": "4SCAR-T Therapy Post CD19-targeted Immunotherapy",
      "status": "TERMINATED",
      "last_update": "2026-08-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04752163",
      "title": "DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04845035",
      "title": "Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2024-02-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04872790",
      "title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05020678",
      "title": "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05032183",
      "title": "Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05054465",
      "title": "A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL",
      "status": "UNKNOWN",
      "last_update": "2021-09-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05292898",
      "title": "A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303792",
      "title": "Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05348889",
      "title": "First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05379647",
      "title": "Natural Killer (NK) Cell Therapy for B-Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2022-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05453500",
      "title": "Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05457556",
      "title": "Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05968170",
      "title": "TCR\u03b1\u03b2/CD19 Depletion of Stem Cell Grafts for Transplant",
      "status": "WITHDRAWN",
      "last_update": "2025-07-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06220097",
      "title": "Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06503094",
      "title": "CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06539338",
      "title": "A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07043218",
      "title": "A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07166419",
      "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07166549",
      "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07674823",
      "title": "Study Of KITE-753 in R/R B-Cell ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 27,
     "n_observational": 0,
     "n_active": 14,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT02727803",
       "title": "Personalized NK Cell Therapy in CBT",
       "status": "RECRUITING",
       "last_update": "2026-07-30",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04318678",
       "title": "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)",
       "status": "RECRUITING",
       "last_update": "2026-05-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05418088",
       "title": "Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-05-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05618041",
       "title": "The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies",
       "status": "RECRUITING",
       "last_update": "2025-06-24",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06364423",
       "title": "Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",
       "status": "RECRUITING",
       "last_update": "2026-07-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07470073",
       "title": "A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults",
       "status": "RECRUITING",
       "last_update": "2026-03-13",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07523555",
       "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00176475",
       "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
       "status": "TERMINATED",
       "last_update": "2013-09-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00427557",
       "title": "Cellular Therapy With Cord Blood Cells",
       "status": "COMPLETED",
       "last_update": "2012-05-28",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00521261",
       "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2014-03-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01362452",
       "title": "Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells",
       "status": "COMPLETED",
       "last_update": "2017-08-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01619761",
       "title": "NK Cells in Cord Blood Transplantation",
       "status": "UNKNOWN",
       "last_update": "2020-02-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01735604",
       "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy",
       "status": "UNKNOWN",
       "last_update": "2015-09-29",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02790515",
       "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-08-12",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03097770",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
       "status": "COMPLETED",
       "last_update": "2020-09-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03615105",
       "title": "Donor Stem Cell Transplantation Using \u03b1/\u03b2+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors",
       "status": "TERMINATED",
       "last_update": "2025-04-06",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04016129",
       "title": "CAR-T Immunotherapy Targeting CD19- ALL",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04049383",
       "title": "CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL",
       "status": "TERMINATED",
       "last_update": "2026-01-12",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04430530",
       "title": "4SCAR-T Therapy Post CD19-targeted Immunotherapy",
       "status": "TERMINATED",
       "last_update": "2026-08-24",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05020678",
       "title": "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-04-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05379647",
       "title": "Natural Killer (NK) Cell Therapy for B-Cell Malignancies",
       "status": "UNKNOWN",
       "last_update": "2022-05-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05968170",
       "title": "TCR\u03b1\u03b2/CD19 Depletion of Stem Cell Grafts for Transplant",
       "status": "WITHDRAWN",
       "last_update": "2025-07-14",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06220097",
       "title": "Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-07-17",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06503094",
       "title": "CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors",
       "status": "UNKNOWN",
       "last_update": "2024-07-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07043218",
       "title": "A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-06-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07166419",
       "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07166549",
       "title": "Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-12-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD20",
     "rituximab"
    ]
   }
  },
  "by_drug": {
   "ASCIMINIB": {
    "n": 9,
    "n_observational": 1,
    "n_active": 8,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03595917",
      "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",
      "status": "RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06308588",
      "title": "Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985485",
      "title": "Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07040982",
      "title": "Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07250087",
      "title": "Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL",
      "status": "RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387926",
      "title": "Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06773936",
      "title": "Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AT-9283": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00443976",
      "title": "Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00522990",
      "title": "Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias",
      "status": "TERMINATED",
      "last_update": "2024-08-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01431664",
      "title": "AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AXICABTAGENE CILOLEUCEL": {
    "n": 1,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03642626",
      "title": "MT2017-45: CAR-T Cell Therapy for Heme Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BAFETINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00352677",
      "title": "Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2009-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BARICITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06475820",
      "title": "Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-08-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BL22": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00024115",
      "title": "BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00077493",
      "title": "BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma",
      "status": "SUSPENDED",
      "last_update": "2007-12-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BLINATUMOMAB": {
    "n": 139,
    "n_observational": 7,
    "n_active": 100,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT01371630",
      "title": "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02877303",
      "title": "Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03150693",
      "title": "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03263572",
      "title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03595917",
      "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",
      "status": "RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03643276",
      "title": "Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017",
      "status": "RECRUITING",
      "last_update": "2025-04-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03739814",
      "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03959085",
      "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04260022",
      "title": "Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04307576",
      "title": "A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04546399",
      "title": "A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04746209",
      "title": "Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT",
      "status": "RECRUITING",
      "last_update": "2021-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05029531",
      "title": "Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)",
      "status": "RECRUITING",
      "last_update": "2024-06-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327894",
      "title": "Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05519579",
      "title": "Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05645718",
      "title": "Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05827549",
      "title": "Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05848687",
      "title": "TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",
      "status": "RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06061094",
      "title": "Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT",
      "status": "RECRUITING",
      "last_update": "2025-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06124157",
      "title": "A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06220487",
      "title": "A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL",
      "status": "RECRUITING",
      "last_update": "2024-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06237192",
      "title": "MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients",
      "status": "RECRUITING",
      "last_update": "2024-02-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06250959",
      "title": "RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.",
      "status": "RECRUITING",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06257394",
      "title": "Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06287229",
      "title": "Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06308588",
      "title": "Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06317662",
      "title": "Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06339775",
      "title": "Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation",
      "status": "RECRUITING",
      "last_update": "2024-04-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06387121",
      "title": "Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06393985",
      "title": "Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06507514",
      "title": "Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533748",
      "title": "Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06554626",
      "title": "Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06607419",
      "title": "Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2024-09-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06742515",
      "title": "Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764238",
      "title": "Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06860269",
      "title": "A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06882057",
      "title": "Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2025-08-26",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06886074",
      "title": "Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985485",
      "title": "Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07003737",
      "title": "Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07059156",
      "title": "Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL",
      "status": "RECRUITING",
      "last_update": "2025-07-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07105579",
      "title": "Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07133997",
      "title": "Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07152041",
      "title": "Newly-diagnosed Pediatric Ph-positive B-ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227584",
      "title": "ALL Backbone in AYAs",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387926",
      "title": "Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07454226",
      "title": "ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493161",
      "title": "Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07495631",
      "title": "Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07564453",
      "title": "Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07570173",
      "title": "A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07677878",
      "title": "Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00560794",
      "title": "Phase II Study of the BiTE\u00ae Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2015-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207388",
      "title": "Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-02-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01209286",
      "title": "Study of the BiTE\u00ae Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2017-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01466179",
      "title": "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01471782",
      "title": "Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-02-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02000427",
      "title": "Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2024-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02003222",
      "title": "Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02013167",
      "title": "Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2024-03-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02101853",
      "title": "Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02143414",
      "title": "Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02393859",
      "title": "Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2026-06-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02412306",
      "title": "Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-12-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02458014",
      "title": "Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease",
      "status": "COMPLETED",
      "last_update": "2025-09-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02744768",
      "title": "D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2018-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02790515",
      "title": "Provision of TCR\u03b3\u03b4 T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na\u00efve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02807883",
      "title": "Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-01-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02879695",
      "title": "Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02997761",
      "title": "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03109093",
      "title": "Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03114865",
      "title": "A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03117751",
      "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03147612",
      "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03160079",
      "title": "Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts",
      "status": "COMPLETED",
      "last_update": "2025-11-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03367299",
      "title": "Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03476239",
      "title": "Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2023-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03480438",
      "title": "Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab",
      "status": "COMPLETED",
      "last_update": "2025-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03512405",
      "title": "Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03518112",
      "title": "Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03523429",
      "title": "PETHEMA-BLIN-01/PET069014 (BLIN-01)",
      "status": "TERMINATED",
      "last_update": "2022-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03541083",
      "title": "Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03628053",
      "title": "Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2020-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03709719",
      "title": "Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2021-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03751709",
      "title": "Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL",
      "status": "COMPLETED",
      "last_update": "2025-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849651",
      "title": "TCR\u03b1\u03b2-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03914625",
      "title": "A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03982992",
      "title": "Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab",
      "status": "WITHDRAWN",
      "last_update": "2024-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04044560",
      "title": "Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2022-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04329325",
      "title": "Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04334993",
      "title": "Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study",
      "status": "UNKNOWN",
      "last_update": "2021-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04448834",
      "title": "Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL",
      "status": "WITHDRAWN",
      "last_update": "2022-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04506086",
      "title": "Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2025-05-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04521231",
      "title": "A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04524455",
      "title": "Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL",
      "status": "COMPLETED",
      "last_update": "2024-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04530565",
      "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04554485",
      "title": "Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04556084",
      "title": "Blinatumomab Bridging Therapy for BALL",
      "status": "TERMINATED",
      "last_update": "2025-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04604691",
      "title": "Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)",
      "status": "UNKNOWN",
      "last_update": "2022-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04688983",
      "title": "Study in Adult Ph-positive ALL",
      "status": "UNKNOWN",
      "last_update": "2020-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04722848",
      "title": "Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04723342",
      "title": "Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot",
      "status": "UNKNOWN",
      "last_update": "2021-01-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04785547",
      "title": "ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT",
      "status": "TERMINATED",
      "last_update": "2024-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04872790",
      "title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04994717",
      "title": "Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05182385",
      "title": "Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05192889",
      "title": "Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303792",
      "title": "Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05557110",
      "title": "Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05559450",
      "title": "Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL",
      "status": "UNKNOWN",
      "last_update": "2022-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05931757",
      "title": "A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054113",
      "title": "Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06075238",
      "title": "Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06111625",
      "title": "Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL",
      "status": "UNKNOWN",
      "last_update": "2023-11-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06125106",
      "title": "Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab",
      "status": "UNKNOWN",
      "last_update": "2023-11-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06438796",
      "title": "Blinatumomab Maintenance After Allo-HSCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06649006",
      "title": "Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06658938",
      "title": "Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-10-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06763302",
      "title": "NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-01-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06773936",
      "title": "Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06930105",
      "title": "Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06991920",
      "title": "Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07134088",
      "title": "A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07153796",
      "title": "A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07178912",
      "title": "Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07192237",
      "title": "Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07199855",
      "title": "Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223190",
      "title": "A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07283640",
      "title": "A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07297914",
      "title": "Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07301424",
      "title": "Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07313852",
      "title": "A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07443592",
      "title": "Treatment for Ph-negative ALL for Adults up to 65 Years",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476729",
      "title": "International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07614022",
      "title": "A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07636564",
      "title": "Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07643103",
      "title": "Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07723911",
      "title": "A Study of Injectable BLB101 and Blincyto\u00ae in Adult Participants With R/R CD19+ B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BOSUTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02311998",
      "title": "Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML",
      "status": "COMPLETED",
      "last_update": "2023-07-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02551718",
      "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BREXUCABTAGENE AUTOLEUCEL": {
    "n": 7,
    "n_observational": 1,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06144606",
      "title": "Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06287229",
      "title": "Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02614066",
      "title": "A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)",
      "status": "COMPLETED",
      "last_update": "2024-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02625480",
      "title": "Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-04-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03642626",
      "title": "MT2017-45: CAR-T Cell Therapy for Heme Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05993949",
      "title": "Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253663",
      "title": "Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COLTUXIMAB RAVTANSINE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01440179",
      "title": "SAR3419 in Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2022-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DASATINIB": {
    "n": 82,
    "n_observational": 3,
    "n_active": 25,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT03595917",
      "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",
      "status": "RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04603872",
      "title": "CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2020-10-28",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04747912",
      "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05751044",
      "title": "HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06124157",
      "title": "A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06257394",
      "title": "Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06336395",
      "title": "Ma-Spore ALL 2020 Study",
      "status": "RECRUITING",
      "last_update": "2024-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06390319",
      "title": "Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533748",
      "title": "Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06855810",
      "title": "Newly-diagnosed Pediatric T-cell ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2025-08-26",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07152041",
      "title": "Newly-diagnosed Pediatric Ph-positive B-ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07203352",
      "title": "Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036738",
      "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "COMPLETED",
      "last_update": "2020-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101595",
      "title": "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00103701",
      "title": "BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123487",
      "title": "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML",
      "status": "COMPLETED",
      "last_update": "2014-11-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00298987",
      "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2010-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00316953",
      "title": "Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2013-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00337454",
      "title": "Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00345826",
      "title": "Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00349518",
      "title": "Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00390793",
      "title": "Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00391989",
      "title": "Treatment of Adult Ph+ LAL With BMS-354825",
      "status": "COMPLETED",
      "last_update": "2017-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00500006",
      "title": "A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)",
      "status": "TERMINATED",
      "last_update": "2015-01-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00529763",
      "title": "Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects",
      "status": "COMPLETED",
      "last_update": "2023-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00549848",
      "title": "Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-08-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00608361",
      "title": "Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2015-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720109",
      "title": "Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-04-13",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00792948",
      "title": "Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00816283",
      "title": "Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2012-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00860535",
      "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)",
      "status": "TERMINATED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00940524",
      "title": "Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00978731",
      "title": "Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study",
      "status": "COMPLETED",
      "last_update": "2011-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00982488",
      "title": "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01004497",
      "title": "First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL",
      "status": "COMPLETED",
      "last_update": "2015-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030718",
      "title": "Rollover Study of BMS-354825 in Patients With CML and Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2010-12-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01077544",
      "title": "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207440",
      "title": "Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01256398",
      "title": "Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01310010",
      "title": "Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01460160",
      "title": "Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01609816",
      "title": "Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2020-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01643603",
      "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2020-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01667133",
      "title": "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2022-06-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01724879",
      "title": "Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)",
      "status": "COMPLETED",
      "last_update": "2022-01-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01883219",
      "title": "TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02043587",
      "title": "Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-05-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02143414",
      "title": "Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420717",
      "title": "Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02494882",
      "title": "Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02523976",
      "title": "Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02551718",
      "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02690922",
      "title": "Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients",
      "status": "UNKNOWN",
      "last_update": "2016-02-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02744768",
      "title": "D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2018-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02779283",
      "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02815059",
      "title": "Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",
      "status": "WITHDRAWN",
      "last_update": "2018-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02819804",
      "title": "Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2020-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02883049",
      "title": "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations",
      "status": "COMPLETED",
      "last_update": "2026-06-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02888990",
      "title": "Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03020030",
      "title": "Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03023046",
      "title": "Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03117751",
      "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03414450",
      "title": "Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2018-10-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03515200",
      "title": "Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2020-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03564470",
      "title": "Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL",
      "status": "UNKNOWN",
      "last_update": "2022-07-01",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03624530",
      "title": "Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants",
      "status": "UNKNOWN",
      "last_update": "2018-08-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04329325",
      "title": "Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04530565",
      "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04845035",
      "title": "Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2024-02-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04872790",
      "title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04996160",
      "title": "Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024357",
      "title": "A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL",
      "status": "UNKNOWN",
      "last_update": "2021-10-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05026229",
      "title": "A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL",
      "status": "UNKNOWN",
      "last_update": "2021-10-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05192889",
      "title": "Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05523661",
      "title": "Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients",
      "status": "UNKNOWN",
      "last_update": "2023-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05993949",
      "title": "Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06773936",
      "title": "Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07301424",
      "title": "Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DENINTUZUMAB MAFODOTIN": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01786096",
      "title": "A Safety Study of SGN-CD19A for Leukemia and Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01786135",
      "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EPRATUZUMAB": {
    "n": 15,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT00003337",
      "title": "Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003338",
      "title": "Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-16",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004084",
      "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004086",
      "title": "Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2009-06-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004107",
      "title": "Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2011-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00098839",
      "title": "Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2017-12-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00941928",
      "title": "Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2014-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00945815",
      "title": "S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01219816",
      "title": "Multi-centric Study",
      "status": "COMPLETED",
      "last_update": "2018-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279707",
      "title": "Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)",
      "status": "UNKNOWN",
      "last_update": "2014-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01354457",
      "title": "Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+",
      "status": "UNKNOWN",
      "last_update": "2014-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01802814",
      "title": "International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010",
      "status": "COMPLETED",
      "last_update": "2024-02-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02577094",
      "title": "Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2026-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476729",
      "title": "International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EPRATUZUMAB-CYS-TESIRINE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03698552",
      "title": "ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-12-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FLUMATINIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04375683",
      "title": "Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL",
      "status": "UNKNOWN",
      "last_update": "2022-03-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05071482",
      "title": "Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL",
      "status": "TERMINATED",
      "last_update": "2025-05-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05433532",
      "title": "Study of Azacitidine\uff0cVenetoclax\uff0cand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients",
      "status": "COMPLETED",
      "last_update": "2024-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IDASANUTLIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04029688",
      "title": "A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-12-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IMATINIB": {
    "n": 86,
    "n_observational": 3,
    "n_active": 9,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04307576",
      "title": "A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06061094",
      "title": "Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT",
      "status": "RECRUITING",
      "last_update": "2025-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06124157",
      "title": "A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06336395",
      "title": "Ma-Spore ALL 2020 Study",
      "status": "RECRUITING",
      "last_update": "2024-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002514",
      "title": "Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission",
      "status": "COMPLETED",
      "last_update": "2023-06-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004932",
      "title": "STI571 in Treating Patients With Recurrent Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00015860",
      "title": "STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022737",
      "title": "Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-02-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00025415",
      "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction",
      "status": "COMPLETED",
      "last_update": "2013-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00036738",
      "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "COMPLETED",
      "last_update": "2020-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00038610",
      "title": "Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00039377",
      "title": "Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00049569",
      "title": "Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-10-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00061945",
      "title": "Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00064285",
      "title": "Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer",
      "status": "COMPLETED",
      "last_update": "2010-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00081133",
      "title": "Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101595",
      "title": "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00109707",
      "title": "A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00123487",
      "title": "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML",
      "status": "COMPLETED",
      "last_update": "2014-11-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00130195",
      "title": "Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2008-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00137111",
      "title": "Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00149136",
      "title": "Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.",
      "status": "UNKNOWN",
      "last_update": "2007-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00154349",
      "title": "Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00167180",
      "title": "Post Transplant Donor Lymphocyte Infusion",
      "status": "TERMINATED",
      "last_update": "2019-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171223",
      "title": "An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00171249",
      "title": "An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00199186",
      "title": "Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "UNKNOWN",
      "last_update": "2007-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244829",
      "title": "Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00287105",
      "title": "Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children",
      "status": "COMPLETED",
      "last_update": "2023-05-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00298987",
      "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2010-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00316953",
      "title": "Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate",
      "status": "COMPLETED",
      "last_update": "2013-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00327678",
      "title": "Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults",
      "status": "COMPLETED",
      "last_update": "2016-06-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00337454",
      "title": "Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan",
      "status": "COMPLETED",
      "last_update": "2011-04-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00349518",
      "title": "Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL",
      "status": "WITHDRAWN",
      "last_update": "2016-02-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00352677",
      "title": "Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2009-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00376467",
      "title": "STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2014-02-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00384228",
      "title": "A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00388895",
      "title": "Glivec in Ph Positive Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2008-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00458848",
      "title": "Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00476190",
      "title": "ALL Adult Consortium Trial: Adult ALL Trial",
      "status": "COMPLETED",
      "last_update": "2025-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00529763",
      "title": "Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects",
      "status": "COMPLETED",
      "last_update": "2023-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00618501",
      "title": "Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00702403",
      "title": "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML",
      "status": "COMPLETED",
      "last_update": "2017-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00763763",
      "title": "Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive",
      "status": "COMPLETED",
      "last_update": "2011-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00852709",
      "title": "Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias",
      "status": "TERMINATED",
      "last_update": "2018-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00860535",
      "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)",
      "status": "TERMINATED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00882206",
      "title": "Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00973752",
      "title": "Treatment of Older Adults With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00982488",
      "title": "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00990249",
      "title": "Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2018-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01005758",
      "title": "Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01005914",
      "title": "Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2023-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01025505",
      "title": "Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study",
      "status": "COMPLETED",
      "last_update": "2022-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030718",
      "title": "Rollover Study of BMS-354825 in Patients With CML and Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2010-12-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01066468",
      "title": "Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec\u00ae Indicated Hematological Disorders.",
      "status": "TERMINATED",
      "last_update": "2012-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01077544",
      "title": "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01085617",
      "title": "Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": null,
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01222013",
      "title": "Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)",
      "status": "SUSPENDED",
      "last_update": "2013-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279473",
      "title": "Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01312818",
      "title": "Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01319981",
      "title": "Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01383447",
      "title": "Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01429610",
      "title": "Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2018-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01491763",
      "title": "Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE",
      "status": "UNKNOWN",
      "last_update": "2022-01-19",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01616238",
      "title": "A Study for Older Adults With Acute Lymphoblastic Leukaemia",
      "status": "COMPLETED",
      "last_update": "2023-08-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01665001",
      "title": "Personalized Therapy of Precursor Lymphoid Neoplasms",
      "status": "UNKNOWN",
      "last_update": "2012-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01883219",
      "title": "TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02272777",
      "title": "A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02352558",
      "title": "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02538926",
      "title": "Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2018-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02551718",
      "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611492",
      "title": "A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults",
      "status": "UNKNOWN",
      "last_update": "2019-10-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02881086",
      "title": "Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment",
      "status": "COMPLETED",
      "last_update": "2025-12-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02894645",
      "title": "Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study",
      "status": "UNKNOWN",
      "last_update": "2016-09-30",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03007147",
      "title": "Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03023046",
      "title": "Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03589326",
      "title": "A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03624530",
      "title": "Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants",
      "status": "UNKNOWN",
      "last_update": "2018-08-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04688983",
      "title": "Study in Adult Ph-positive ALL",
      "status": "UNKNOWN",
      "last_update": "2020-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04722848",
      "title": "Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05071482",
      "title": "Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL",
      "status": "TERMINATED",
      "last_update": "2025-05-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05306301",
      "title": "Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "INOTUZUMAB": {
    "n": 53,
    "n_observational": 4,
    "n_active": 32,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT01371630",
      "title": "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02877303",
      "title": "Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03104491",
      "title": "Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03150693",
      "title": "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03739814",
      "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03959085",
      "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04307576",
      "title": "A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04747912",
      "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05645718",
      "title": "Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05748171",
      "title": "A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940961",
      "title": "Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06287229",
      "title": "Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06387121",
      "title": "Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533748",
      "title": "Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06554626",
      "title": "Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06863259",
      "title": "Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985485",
      "title": "Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493161",
      "title": "Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07495631",
      "title": "Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01134575",
      "title": "CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01363297",
      "title": "Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01564784",
      "title": "A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-01-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01925131",
      "title": "S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02311998",
      "title": "Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML",
      "status": "COMPLETED",
      "last_update": "2023-07-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02981628",
      "title": "Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03094611",
      "title": "Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-04-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03249870",
      "title": "Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL",
      "status": "COMPLETED",
      "last_update": "2026-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03441061",
      "title": "Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03460522",
      "title": "Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL",
      "status": "UNKNOWN",
      "last_update": "2022-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03488225",
      "title": "Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03564678",
      "title": "Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610438",
      "title": "Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03628053",
      "title": "Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2020-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03677596",
      "title": "A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients",
      "status": "COMPLETED",
      "last_update": "2023-11-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03851081",
      "title": "Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2022-01-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03856216",
      "title": "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03913559",
      "title": "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03962465",
      "title": "Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL",
      "status": "UNKNOWN",
      "last_update": "2023-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03991884",
      "title": "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04530565",
      "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05016947",
      "title": "Venetoclax Plus Inotuzumab for B-ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303792",
      "title": "Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05456698",
      "title": "Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05687032",
      "title": "A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-12-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06087419",
      "title": "A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients",
      "status": "UNKNOWN",
      "last_update": "2023-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427330",
      "title": "Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2024-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06861348",
      "title": "Effectiveness and Safety of InO\u00b1DLI for Relapsed B-ALL/LBL After Allo-HSCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985498",
      "title": "Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL",
      "status": "SUSPENDED",
      "last_update": "2026-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07313852",
      "title": "A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07443488",
      "title": "Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476729",
      "title": "International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07643103",
      "title": "Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07770698",
      "title": "A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "INOTUZUMAB OZOGAMICIN": {
    "n": 52,
    "n_observational": 6,
    "n_active": 31,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT01371630",
      "title": "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02877303",
      "title": "Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03104491",
      "title": "Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03150693",
      "title": "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03739814",
      "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03959085",
      "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04307576",
      "title": "A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04747912",
      "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05645718",
      "title": "Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05748171",
      "title": "A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05940961",
      "title": "Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL",
      "status": "RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06287229",
      "title": "Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06387121",
      "title": "Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533748",
      "title": "Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06554626",
      "title": "Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06863259",
      "title": "Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985485",
      "title": "Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493161",
      "title": "Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07495631",
      "title": "Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01134575",
      "title": "CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01363297",
      "title": "Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01564784",
      "title": "A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2019-01-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01925131",
      "title": "S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-05-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02311998",
      "title": "Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML",
      "status": "COMPLETED",
      "last_update": "2023-07-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02981628",
      "title": "Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03094611",
      "title": "Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-04-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03249870",
      "title": "Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL",
      "status": "COMPLETED",
      "last_update": "2026-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03441061",
      "title": "Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03460522",
      "title": "Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL",
      "status": "UNKNOWN",
      "last_update": "2022-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03488225",
      "title": "Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03564678",
      "title": "Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03610438",
      "title": "Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03628053",
      "title": "Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2020-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03677596",
      "title": "A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients",
      "status": "COMPLETED",
      "last_update": "2023-11-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03851081",
      "title": "Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2022-01-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03856216",
      "title": "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03913559",
      "title": "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03962465",
      "title": "Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL",
      "status": "UNKNOWN",
      "last_update": "2023-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03991884",
      "title": "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04530565",
      "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05016947",
      "title": "Venetoclax Plus Inotuzumab for B-ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05303792",
      "title": "Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05456698",
      "title": "Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05687032",
      "title": "A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2025-12-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06087419",
      "title": "A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients",
      "status": "UNKNOWN",
      "last_update": "2023-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427330",
      "title": "Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2024-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06861348",
      "title": "Effectiveness and Safety of InO\u00b1DLI for Relapsed B-ALL/LBL After Allo-HSCT",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06985498",
      "title": "Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL",
      "status": "SUSPENDED",
      "last_update": "2026-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07443488",
      "title": "Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07476729",
      "title": "International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07643103",
      "title": "Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07770698",
      "title": "A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "KW-2449": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00346632",
      "title": "An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2024-05-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LESTAURTINIB": {
    "n": 1,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00557193",
      "title": "Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2024-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LONCASTUXIMAB TESIRINE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02669264",
      "title": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)",
      "status": "TERMINATED",
      "last_update": "2021-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MOXETUMOMAB PASUDOTOX": {
    "n": 5,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00077493",
      "title": "BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma",
      "status": "SUSPENDED",
      "last_update": "2007-12-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00659425",
      "title": "CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01891981",
      "title": "Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2023-10-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02227108",
      "title": "Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02338050",
      "title": "Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2015-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NILOTINIB": {
    "n": 24,
    "n_observational": 2,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00036738",
      "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib",
      "status": "COMPLETED",
      "last_update": "2020-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00109707",
      "title": "A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00384228",
      "title": "A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00702403",
      "title": "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML",
      "status": "COMPLETED",
      "last_update": "2017-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00750659",
      "title": "Nilotinib Pre and Post Allogeneic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2016-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00844298",
      "title": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00860535",
      "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)",
      "status": "TERMINATED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00905398",
      "title": "Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2015-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01025505",
      "title": "Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study",
      "status": "COMPLETED",
      "last_update": "2022-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01077544",
      "title": "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2020-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207440",
      "title": "Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01279473",
      "title": "Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01528085",
      "title": "Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01667133",
      "title": "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2022-06-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01670084",
      "title": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01735955",
      "title": "Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study",
      "status": "COMPLETED",
      "last_update": "2024-02-08",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01743989",
      "title": "A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.",
      "status": "COMPLETED",
      "last_update": "2021-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01883219",
      "title": "TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081378",
      "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02272777",
      "title": "A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",
      "status": "COMPLETED",
      "last_update": "2019-08-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02551718",
      "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02611492",
      "title": "A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults",
      "status": "UNKNOWN",
      "last_update": "2019-10-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493408",
      "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NILOTINIB HYDROCHLORIDE": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01670084",
      "title": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2015-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02551718",
      "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBECABTAGENE AUTOLEUCEL": {
    "n": 4,
    "n_observational": 1,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06173518",
      "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",
      "status": "RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07053059",
      "title": "Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07400029",
      "title": "A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04404660",
      "title": "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OLVEREMBATINIB": {
    "n": 16,
    "n_observational": 0,
    "n_active": 14,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05495035",
      "title": "Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06051409",
      "title": "A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)",
      "status": "RECRUITING",
      "last_update": "2026-04-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06082934",
      "title": "Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-na\u00efve Ph+ Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2023-10-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06220487",
      "title": "A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL",
      "status": "RECRUITING",
      "last_update": "2024-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06481228",
      "title": "Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2026-03-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06754267",
      "title": "Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL",
      "status": "RECRUITING",
      "last_update": "2024-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07074496",
      "title": "Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07152041",
      "title": "Newly-diagnosed Pediatric Ph-positive B-ALL Protocol",
      "status": "RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07454226",
      "title": "ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07493161",
      "title": "Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05466175",
      "title": "A Study of Olverembatinib in the Treatment of Ph+ ALL",
      "status": "UNKNOWN",
      "last_update": "2022-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05594784",
      "title": "Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL",
      "status": "COMPLETED",
      "last_update": "2025-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05931757",
      "title": "A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-07-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06658925",
      "title": "Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07178912",
      "title": "Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07443488",
      "title": "Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PACRITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PONATINIB": {
    "n": 35,
    "n_observational": 8,
    "n_active": 18,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03263572",
      "title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03739814",
      "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03934372",
      "title": "Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04747912",
      "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06061094",
      "title": "Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT",
      "status": "RECRUITING",
      "last_update": "2025-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06207123",
      "title": "A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)",
      "status": "RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06860269",
      "title": "A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-02-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07224100",
      "title": "Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01207440",
      "title": "Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2021-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01424982",
      "title": "Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01641107",
      "title": "Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.",
      "status": "COMPLETED",
      "last_update": "2021-11-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01667133",
      "title": "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)",
      "status": "COMPLETED",
      "last_update": "2022-06-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01883219",
      "title": "TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2017-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02551718",
      "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02629692",
      "title": "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to \u22653 Prior CML Therapies",
      "status": "TERMINATED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02776605",
      "title": "Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia",
      "status": "UNKNOWN",
      "last_update": "2022-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02779283",
      "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03147612",
      "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03576547",
      "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-05-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03589326",
      "title": "A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03624530",
      "title": "Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants",
      "status": "UNKNOWN",
      "last_update": "2018-08-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04233346",
      "title": "The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04475731",
      "title": "Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04501614",
      "title": "A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04530565",
      "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04554459",
      "title": "Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL",
      "status": "TERMINATED",
      "last_update": "2024-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04688983",
      "title": "Study in Adult Ph-positive ALL",
      "status": "UNKNOWN",
      "last_update": "2020-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04722848",
      "title": "Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04845035",
      "title": "Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2024-02-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05268003",
      "title": "A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2026-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05306301",
      "title": "Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07301424",
      "title": "Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07614022",
      "title": "A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02551718",
      "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REVUMENIB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04065399",
      "title": "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation",
      "status": "RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06575296",
      "title": "Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant",
      "status": "RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07356154",
      "title": "A Study of Revumenib and Mezigdomide in People With Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05326516",
      "title": "A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2024-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05761171",
      "title": "A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07283640",
      "title": "A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07498465",
      "title": "A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2026-05-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07636564",
      "title": "Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RUXOLITINIB": {
    "n": 30,
    "n_observational": 0,
    "n_active": 14,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03571321",
      "title": "Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05088226",
      "title": "Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05745714",
      "title": "HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06128070",
      "title": "Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",
      "status": "RECRUITING",
      "last_update": "2025-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06477549",
      "title": "BeFluBu vs FluBuRux Conditioning in Haploidentical HCT",
      "status": "RECRUITING",
      "last_update": "2024-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06551584",
      "title": "Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT",
      "status": "RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06756152",
      "title": "Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis",
      "status": "RECRUITING",
      "last_update": "2025-01-01",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07356245",
      "title": "Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07366801",
      "title": "Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-01-26",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07454226",
      "title": "ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00674479",
      "title": "INCB018424 in Patients With Advanced Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164163",
      "title": "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",
      "status": "COMPLETED",
      "last_update": "2014-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01251965",
      "title": "Phase l/II Study of Ruxolitinib for Acute Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01620216",
      "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia",
      "status": "TERMINATED",
      "last_update": "2021-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01914484",
      "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-11-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420717",
      "title": "Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2025-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02494882",
      "title": "Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02551718",
      "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02723994",
      "title": "A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02779283",
      "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03117751",
      "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03515200",
      "title": "Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia",
      "status": "TERMINATED",
      "last_update": "2020-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03613428",
      "title": "Ruxolitinib Plus LVP in Patients With R/R ETP-ALL",
      "status": "UNKNOWN",
      "last_update": "2018-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04669210",
      "title": "PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT",
      "status": "COMPLETED",
      "last_update": "2025-07-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04996160",
      "title": "Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2026-04-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05075681",
      "title": "Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-12-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05663827",
      "title": "Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease",
      "status": "COMPLETED",
      "last_update": "2024-03-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07297914",
      "title": "Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-22",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TAFASITAMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05366218",
      "title": "Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia",
      "status": "RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01685021",
      "title": "Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)",
      "status": "TERMINATED",
      "last_update": "2018-02-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05453500",
      "title": "Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TISAGENLECLEUCEL": {
    "n": 14,
    "n_observational": 4,
    "n_active": 6,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT04094311",
      "title": "Study of Out of Specification for Tisagenlecleucel",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05310591",
      "title": "Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence",
      "status": "RECRUITING",
      "last_update": "2024-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06408194",
      "title": "Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02167360",
      "title": "Study of Efficacy and Safety of CTL019 in Adult ALL Patients",
      "status": "WITHDRAWN",
      "last_update": "2017-02-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02228096",
      "title": "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients",
      "status": "COMPLETED",
      "last_update": "2020-11-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02435849",
      "title": "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients",
      "status": "COMPLETED",
      "last_update": "2024-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02529813",
      "title": "CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03123939",
      "title": "Phase III B in Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-07-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03628053",
      "title": "Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2020-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03642626",
      "title": "MT2017-45: CAR-T Cell Therapy for Heme Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03876769",
      "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04156659",
      "title": "Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL",
      "status": "WITHDRAWN",
      "last_update": "2023-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04225676",
      "title": "Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)",
      "status": "TERMINATED",
      "last_update": "2023-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05460533",
      "title": "A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VODOBATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02629692",
      "title": "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to \u22653 Prior CML Therapies",
      "status": "TERMINATED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "XL-228": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00464113",
      "title": "Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2015-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "YTTRIUM Y 90 EPRATUZUMAB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT00004084",
      "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004086",
      "title": "Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2009-06-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004107",
      "title": "Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2011-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01354457",
      "title": "Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+",
      "status": "UNKNOWN",
      "last_update": "2014-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02577094",
      "title": "Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia",
      "status": "WITHDRAWN",
      "last_update": "2026-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}